Posts Tagged Epilepsy

[Abstract + References] Awareness and current knowledge of epilepsy

Abstract

Epilepsy is a severe neural disorder that affects approximately fifty million individuals globally. Despite the fact that for most of the people with epilepsy, convulsions are better controlled by current accessible antiepileptic medicines, yet there are more than 30% of individuals affected with medically intractable epilepsy and around 30–40% of all patients with epilepsy affected by many adverse reactions and convulsion resistance to the present antiepileptic drugs. Consequently, various scientists attempt to develop new strategies to treat epilepsy, for instance, to find out novel antiepileptic ingredients from traditional medicines. This work aims to present a complete summary of natural medicines prescribed as antiepileptic agents all over the world by ethnic groups and different tribes. We undertook an extensive bibliographic analysis by searching peer reviewed papers and classical textbooks and further consulting well accepted worldwide scientific databases. We carried out PubMed, EMbase and CENTRAL searches by means of terms such as “antiepileptic” and “anti-convulsant” activity of plants. Medicinal plants have been prescribed to treat epilepsy and have been recognized as antiepileptic medicines. In this review, a variety of herbs have been reviewed for thorough studies such as Cuminum cyminum, Butea monosperma, Solanum americanum, Anacyclus pyrethrum, Leonotis leonurus, Elaeocarpus ganitrus and Angelica archangelica. This paper shows that it was high time experimental studies are increased to obtain novel potential active principles from medicinal plants. Plant extracts and their chemical constituents should be further evaluated to clarify their mechanisms of action. This paper provides a solid base upon which to further investigate the clinical efficacy of medicinal plants that are both currently prescribed by physicians as traditional antiepileptic agents, but also could be effective as an antiepileptic drug with further research and study.

References

  1. Abou-Khalil B (2008) Levetiracetam in the treatment of epilepsy. Neuropsychiat Dis Treat 4:507CrossRefGoogle Scholar
  2. Achliya GS, Wadodkar SG, Dorle AK (2004) Evaluation of sedative and anticonvulsant activities of Unmadnashak Ghrita. J Ethnopharmacol 94:77–83PubMedCrossRefGoogle Scholar
  3. Achliya G, Wadodkar S, Dorle A (2005) Evaluation of CNS activity of Bramhi Ghrita. Ind J Pharmacol 37:33CrossRefGoogle Scholar
  4. Aderounmua A, Omonisib A, Akingbasotec J, Makanjuolad M, Bejide R, Orafidiya L, Adelusolae K (2013) Wound-healing and potential anti-keloidal properties of the latex of Calotropis procera (Aiton) Asclepiadaceae in rabbits. Afric J Trad Complement Altern Med 10:574–579Google Scholar
  5. Aggarwal BB, Kumar A, Aggarwal MS, Shishodia S (2005) Curcumin derived from turmeric (Curcuma longa): a spice for all seasons. Phytopharmaceut Cancer Chemoprevent 23:351–387Google Scholar
  6. Aggarwal BB, Prasad S, Reuter S, Kannappan R, R Yadav V, Park B, Hye Kim J, C Gupta S, Phromnoi K, Sundaram C (2011) Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases:“reverse pharmacology” and “bedside to bench” approach. Curr Drug Targets 12:1595–1653Google Scholar
  7. Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, Damanhouri ZA, Anwar F (2013) A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed 3:337–352PubMedPubMedCentralCrossRefGoogle Scholar
  8. Akhondian J, Parsa A, Rakhshande H (2007) The effect of Nigella sativa L.(black cumin seed) on intractable pediatric seizures. Med Sci Monit 13:CR555–CR559PubMedGoogle Scholar
  9. Akula K, Dhir A, Kulkarni S (2009) Effect of various antiepileptic drugs in a pentylenetetrazol-induced seizure model in mice. Methods Find Exp Clin Pharmacol 31:423–432PubMedCrossRefGoogle Scholar
  10. Aldarmaa J, Liu Z, Long J, Mo X, Ma J, Liu J (2010) Anti-convulsant effect and mechanism of Astragalus mongholicus extract in vitro and in vivo: protection against oxidative damage and mitochondrial dysfunction. Neurochem Res 35:33PubMedCrossRefGoogle Scholar
  11. Al-Ghamdi M (2001) The anti-inflammatory, analgesic and antipyretic activity of Nigella sativa. J Ethnopharmacol 76:45–48PubMedCrossRefPubMedCentralGoogle Scholar
  12. Aliyu RM, Abubakar MB, Kasarawa AB, Dabai YU, Lawal N, Bello MB, Fardami AY (2015) Efficacy and phytochemical analysis of latex of Calotropis procera against selected dermatophytes. J Intercultural Ethnopharmacol 4:314CrossRefGoogle Scholar
  13. Alldredge BK, Lowenstein DH, Simon RP (1989) Seizures associated with recreational drug abuse. Neurol 39:1037–1037CrossRefGoogle Scholar
  14. Amabeoku G, Green I, Kabatende J (2007) Anticonvulsant activity of Cotyledon orbiculata L.(Crassulaceae) leaf extract in mice. J Ethnopharmacol 112:101–107PubMedCrossRefPubMedCentralGoogle Scholar
  15. Ambrósio AF, Soares-da-Silva P, Carvalho CM, Carvalho AP (2002) Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 27:121–130PubMedCrossRefPubMedCentralGoogle Scholar
  16. Ammon HP, Wahl MA (1991) Pharmacology of Curcuma longa. Planta Med 57:1–7PubMedCrossRefPubMedCentralGoogle Scholar
  17. Ängehagen M, Ben-Menachem E, Rönnbäck L, Hansson E (2003) Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res 28:333–340PubMedCrossRefPubMedCentralGoogle Scholar
  18. Annalakshmi R, Uma R, Chandran GS, Muneeswaran A (2012) A treasure of medicinal herb-Anacyclus pyrethrum a review. Ind J Drugs Dis 1:59–67Google Scholar
  19. Arulmozhi V, Krishnaveni M, Karthishwaran K, Dhamodharan G, Mirunalini S (2010) Antioxidant and antihyperlipidemic effect of Solanum nigrum fruit extract on the experimental model against chronic ethanol toxicity. Pharmacogn Mag 6:42PubMedPubMedCentralCrossRefGoogle Scholar
  20. Asha MK, Debraj D, Edwin JR, Srikanth H, Muruganantham N, Dethe SM, Anirban B, Jaya B, Deepak M, Agarwal A (2013) In vitro anti-helicobacter pylori activity of a flavonoid rich extract of Glycyrrhiza glabra and its probable mechanisms of action. J Ethnopharmacol 145:581–586PubMedCrossRefGoogle Scholar
  21. Avallone R, Zanoli P, Puia G, Kleinschnitz M, Schreier P, Baraldi M (2000) Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochem Pharmacol 59:1387–1394PubMedCrossRefGoogle Scholar
  22. Awad R, Ahmed F, Bourbonnais-Spear N, Mullally M, Ta CA, Tang A, Merali Z, Maquin P, Caal F, Cal V (2009) Ethnopharmacology of Q’eqchi’Maya antiepileptic and anxiolytic plants: effects on the GABAergic system. J Ethnopharmacol 125:257–264PubMedCrossRefGoogle Scholar
  23. Baek N-I, Jeon SG, Ahn E-M, Hahn J-T, Bahn JH, Jang JS, Cho S-W, Park JK, Choi SY (2000) Anticonvulsant compounds from the wood ofCaesalpinia sappan L. Arch Pharm Res 23:344PubMedCrossRefGoogle Scholar
  24. Bagheri SM, Sahebkar A, Gohari AR, Saeidnia S, Malmir M, Iranshahi M (2010) Evaluation of cytotoxicity and anticonvulsant activity of some Iranian medicinal Ferula species. Pharm Biol 48:242–246PubMedCrossRefGoogle Scholar
  25. Balamurugan G, Dharan M, Rajan S (2008) Anti epileptic activity of poly herbal extract from Indian medicinal plants. J Sci Res 1:153–159CrossRefGoogle Scholar
  26. Banach M, Popławska M, Błaszczyk B, Borowicz KK, Czuczwar SJ (2016) Pharmacokinetic/pharmacodynamic considerations for epilepsy–depression comorbidities. Expert Opin Drug Metab Toxicol 12:1067–1080PubMedCrossRefGoogle Scholar
  27. Bandara BR, Kumar NS, Samaranayake KS (1989) An antifungal constituent from the stem bark of Butea monosperma. J Ethnopharmacol 25:73–75PubMedCrossRefGoogle Scholar
  28. Basu A, Chaudhuri AN (1991) Preliminary studies on the antiinflammatory and analgesic activities of Calotropis procera root extract. J Ethnopharmacol 31:319–324PubMedCrossRefGoogle Scholar
  29. Bavarva J, Narasimhacharya A (2008) Preliminary study on antihyperglycemic and antihyperlipaemic effects of Butea monosperma in NIDDM rats. Fitoterap 79:328–331CrossRefGoogle Scholar
  30. Bendjeddou D, Lalaoui K, Satta D (2003) Immunostimulating activity of the hot water-soluble polysaccharide extracts of Anacyclus pyrethrum, Alpinia galanga and Citrullus colocynthis. J Ethnopharmacol 88:155–160PubMedCrossRefGoogle Scholar
  31. Ben-Menachem E (2011) Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand 124:5–15CrossRefGoogle Scholar
  32. Bharti S, Wahane V, Kumar V (2010) Protective effect of Calotropis procera latex extracts on experimentally induced gastric ulcers in rat. J Ethnopharmacol 127:440–444PubMedCrossRefGoogle Scholar
  33. Bhat Z, Kumar D, Shah M (2011) Angelica archangelica Linn. is Angal on earth for the treatment of diseases: A review. Inter J Nutr Pharmacol Neurol Dis 1:35–49Google Scholar
  34. Bhosle V (2013) Anticonvulsant and antioxidant activity of aqueous leaves extract of Desmodium triflorum in mice against pentylenetetrazole and maximal electroshock induced convulsion. Rev Brasileira de Farmacogn 23:692–698CrossRefGoogle Scholar
  35. Bienvenu E, Amabeoku G, Eagles P, Scott G, Springfield E (2002) Anticonvulsant activity of aqueous extract of Leonotis leonurus. Phytomed 9:217–223CrossRefGoogle Scholar
  36. Birbeck G, Chomba E, Atadzhanov M, Mbewe E, Haworth A (2007) The social and economic impact of epilepsy in Zambia: a cross-sectional study. Lancet Neurol 6:39–44PubMedPubMedCentralCrossRefGoogle Scholar
  37. Borrelli F, Milic N, Ascione V, Capasso R, Izzo AA, Capasso F, Petrucci F, Valente R, Fattorusso E, Taglialatela-Scafati O (2005) Isolation of new rotenoids from Boerhaavia diffusa and evaluation of their effect on intestinal motility. Planta Med 71:928–932PubMedCrossRefGoogle Scholar
  38. Boskabady M, Mohsenpoor N, Takaloo L (2010) Antiasthmatic effect of Nigella sativa in airways of asthmatic patients. Phytomed 17:707–713CrossRefGoogle Scholar
  39. Brodie MJ, Kwan P (2012) Current position of phenobarbital in epilepsy and its future. Epilep 53:40–46CrossRefGoogle Scholar
  40. Bum EN, Schmutz M, Meyer C, Rakotonirina A, Bopelet M, Portet C, Jeker A, Rakotonirina S, Olpe H, Herrling P (2001) Anticonvulsant properties of the methanolic extract of Cyperus articulatus (Cyperaceae). J Ethnopharmacol 76:145–150PubMedCrossRefGoogle Scholar
  41. Bum EN, Dawack D, Schmutz M, Rakotonirina A, Rakotonirina S, Portet C, Jeker A, Olpe H, Herrling P (2004) Anticonvulsant activity of Mimosa pudica decoction. Fitoterap 75:309–314CrossRefGoogle Scholar
  42. Bum EN, Naami Y, Soudi S, Rakotonirina S, Rakotonirina A (2005) Psorospermum febrifugum spach (Hypericaceae) decoction antagonized chemically-induced convulsions in mice. Int J Pharm 1:118–121CrossRefGoogle Scholar
  43. Bum EN, Ngoupaye G, Talla E, Dimo T, Nkantchoua GN, Pelanken M, Taiwe G (2008) The anticonvulsant and sedative properties of stems of Cissus quadrangularis in mice. Afric J Pharm Pharmacol 2:042–047Google Scholar
  44. Campbell EL, Chebib M, Johnston GA (2004) The dietary flavonoids apigenin and (−)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABAA receptors. Biochem Pharmacol 68:1631–1638PubMedCrossRefGoogle Scholar
  45. Campo-Soria C, Chang Y, Weiss DS (2006) Mechanism of action of benzodiazepines on GABAA receptors. Brit J Pharmacol 148:984–990CrossRefGoogle Scholar
  46. Castilla-Guerra L, Fernández-Moreno MC, López-Chozas JM, Fernández-Bolaños R (2006) Electrolytes disturbances and seizures. Epilep 47:1990–1998CrossRefGoogle Scholar
  47. Celik S, Kecel-Gunduz S, Ozel AE, Akyuz S (2015) Structural and vibrational study of primidone based on monomer and dimer calculations. J Biomol Struct Dyn 33:911–923PubMedCrossRefGoogle Scholar
  48. Chainani-Wu N (2003) Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9:161–168PubMedCrossRefGoogle Scholar
  49. Chandrasekar S, Bhanumathy M, Pawar A, Somasundaram T (2010) Phytopharmacology of Ficus religiosa. Pharmacogn Rev 4:195PubMedPubMedCentralCrossRefGoogle Scholar
  50. Chen J, Du CY, Lam KY, Zhang WL, Lam CT, Yan AL, Yao P, Lau DT, Dong TT, Tsim KW (2014) The standardized extract of Ziziphus jujuba fruit (jujube) regulates pro-inflammatory cytokine expression in cultured murine macrophages: suppression of lipopolysaccharide-stimulated NF-κB activity. Phytother Res 28:1527–1532PubMedCrossRefGoogle Scholar
  51. Choedon T, Mathan G, Arya S, Kumar VL, Kumar V (2006) Anticancer and cytotoxic properties of the latex of Calotropis procera in a transgenic mouse model of hepatocellular carcinoma. World J Gastroenterol 12:2517PubMedPubMedCentralCrossRefGoogle Scholar
  52. Choedon T, Shukla SK, Kumar V (2010) Chemopreventive and anti-cancer properties of the aqueous extract of flowers of Butea monosperma. J Ethnopharmacol 129:208–213PubMedCrossRefGoogle Scholar
  53. Coimbra N, Castro-Souza C, Segato E, Nora J, Herrero C, Tedeschi-Filho W, Garcia-Cairasco N (2001) Post-ictal analgesia: involvement of opioid, serotoninergic and cholinergic mechanisms. Brain Res 888:314–320PubMedCrossRefGoogle Scholar
  54. Czapinski P, Blaszczyk B, Czuczwar SJ (2005) Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 5:3–14PubMedCrossRefGoogle Scholar
  55. da Cruz GMP, Felipe CFB, Scorza FA, da Costa MAC, Tavares AF, Menezes MLF, de Andrade GM, Leal LKA, Brito GAC, da Graça Naffah-Mazzacoratti M (2013) Piperine decreases pilocarpine-induced convulsions by GABAergic mechanisms. Pharmacol Biochem Behav 104:144–153Google Scholar
  56. Das S, Haldar PK, Pramanik G, Panda SP, Bera S, Basavaiah K, Abdulrahman SA, Basavaiah K, Rajendraprasad N, Ramesh P (2010) Anticonvulsant activity of methanolic extract of Clerodendron infortunatum Linn. In Swiss albino mice. Thai J Pharm Sci 34:129–133Google Scholar
  57. de Carvalho RSM, Duarte FS, de Lima TCM (2011) Involvement of GABAergic non-benzodiazepine sites in the anxiolytic-like and sedative effects of the flavonoid baicalein in mice. Behav Brain Res 221:75–82PubMedCrossRefGoogle Scholar
  58. de Freitas RL, de Oliveira RC, de Carvalho AD, Felippotti TT, Bassi GS, Elias-Filho DH, Coimbra NC (2004) Role of muscarinic and nicotinic cholinergic receptors in an experimental model of epilepsy-induced analgesia. Pharmacol Biochem Behav 79:367–376PubMedCrossRefGoogle Scholar
  59. de Freitas RL, Medeiros P, Khan AU, Coimbra NC (2016) μ1-Opioid receptors in the dorsomedial and ventrolateral columns of the periaqueductal grey matter are critical for the enhancement of post-ictal antinociception. Synapse 70:519–530PubMedCrossRefGoogle Scholar
  60. de Oliveira RC, de Oliveira R, Zanandrea PC, Paschoalin-Maurin T, Coimbra NC (2011) Acetylcholine-mediated neurotransmission within the nucleus raphe magnus exerts a key role in the organization of both interictal and postictal antinociception. Epilepsy Behav 22:178–185PubMedCrossRefGoogle Scholar
  61. de Sousa Lima RC, Silva MCC, Aguiar CCT, Chaves EMC, Dias KCF, Macêdo DS, de Sousa FCF, de Morais Carvalho K, Ramos MV, Vasconcelos SMM (2012) Anticonvulsant action of Calotropis procera latex proteins. Epilepsy Behav 23:123–126CrossRefGoogle Scholar
  62. Debnath J, Sharma UR, Kumar B, Chauhan NS (2010) Anticonvulsant activity of ethanolic extract of fruits of Terminalia chebula on experimental animals. Inter J Drug Develop Res 4:45–60Google Scholar
  63. Dekermendjian K, Kahnberg P, Witt M-R, Sterner O, Nielsen M, Liljefors T (1999) Structure− activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABAA receptor complex. J Med Chem 42:4343–4350PubMedCrossRefGoogle Scholar
  64. Deshmane DN, Gadgoli CH, Halade GV (2007) Anticonvulsant effect of Origanum majorana L. Pharmacol Online 1:64–78Google Scholar
  65. Dhandapani S, Subramanian VR, Rajagopal S, Namasivayam N (2002) Hypolipidemic effect of Cuminum cyminum L. on alloxan-induced diabetic rats. Pharmacol Res 46:251–255PubMedCrossRefGoogle Scholar
  66. Diamantis A, Sidiropoulou K, Magiorkinis E (2010) Epilepsy during the middle ages, the renaissance and the enlightenment. J Neurol 257:691–698PubMedCrossRefGoogle Scholar
  67. Ding X, Zhu F, Gao S (2012) Purification, antitumour and immunomodulatory activity of water-extractable and alkali-extractable polysaccharides from Solanum nigrum L. Food Chem 131:677–684CrossRefGoogle Scholar
  68. Dubé C, Richichi C, Bender RA, Chung G, Litt B, Baram TZ (2006) Temporal lobe epilepsy after experimental prolonged febrile seizures: prospective analysis. Brain 129:911–922PubMedPubMedCentralCrossRefGoogle Scholar
  69. Dudhatra GB, Mody SK, Awale MM, Patel HB, Modi CM, Kumar A, Kamani DR, Chauhan BN (2012) A comprehensive review on pharmacotherapeutics of herbal bioenhancers. Sci World J 2:12–20Google Scholar
  70. Eigner D, Scholz D (1999) Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. J Ethnopharmacol 67:1–6PubMedCrossRefGoogle Scholar
  71. Ekor M (2014) The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 4:177PubMedPubMedCentralCrossRefGoogle Scholar
  72. Engelborghs S, D’hooge R, De Deyn P (2000) Pathophysiology of epilepsy. Acta Neurol Belgica 100:201–213Google Scholar
  73. Felippotti TT, do Carmo DR, Paim LL, Stradiotto NR, de Oliveira Bicalho U, Parada CA, Grillo R, Fraceto LF, Coimbra NC (2011a) Effect of a nanostructured dendrimer-naloxonazine complex on endogenous opioid peptides μ 1 receptor-mediated post-ictal antinociception. Nanomed Nanotechnol Biol Med 7:871–880CrossRefGoogle Scholar
  74. Felippotti TT, dos Reis Ferreira CM, de Freitas RL, de Oliveira RC, de Oliveira R, Paschoalin-Maurin T, Coimbra NC (2011b) Paradoxical effect of noradrenaline-mediated neurotransmission in the antinociceptive phenomenon that accompanies tonic–clonic seizures: role of locus coeruleus neurons and α 2-and β-noradrenergic receptors. Epilepsy Behav 22:165–177PubMedCrossRefGoogle Scholar
  75. Felippotti TT, de Freitas RL, Coimbra NC (2012) Endogenous opioid peptide-mediated neurotransmission in central and pericentral nuclei of the inferior colliculus recruits μ 1-opioid receptor to modulate post-ictal antinociception. Neuropeptides 46:39–47PubMedCrossRefGoogle Scholar
  76. Fiebich BL, Knörle R, Appel K, Kammler T, Weiss G (2011) Pharmacological studies in an herbal drug combination of St. John’s Wort (Hypericum perforatum) and passion flower (Passiflora incarnata): in vitro and in vivo evidence of synergy between Hypericum and Passiflora in antidepressant pharmacological models. Fitoterap 82:474–480CrossRefGoogle Scholar
  77. Fisher RS, Boas WE, Blume W, Elger C, Genton P, Lee P, Engel J (2005) Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilep 46:470–472CrossRefGoogle Scholar
  78. Forsgren L, Beghi E, Oun A, Sillanpää M (2005) The epidemiology of epilepsy in Europe–a systematic review. Eur J Neurol 12:245–253PubMedCrossRefGoogle Scholar
  79. Fraternale D, Flamini G, Ricci D (2014) Essential oil composition and antimicrobial activity of Angelica archangelica L.(Apiaceae) roots. J Med Food 17:1043–1047PubMedCrossRefGoogle Scholar
  80. Freitas RL, Ferreira CM, Ribeiro SJ, Carvalho AD, Elias-Filho DH, Garcia-Cairasco N, Coimbra NC (2005) Intrinsic neural circuits between dorsal midbrain neurons that control fear-induced responses and seizure activity and nuclei of the pain inhibitory system elaborating postictal antinociceptive processes: a functional neuroanatomical and neuropharmacological study. Exp Neurol 191:225–242PubMedCrossRefGoogle Scholar
  81. Freitas RL, Bassi GS, de Oliveira AM, Coimbra NC (2008) Serotonergic neurotransmission in the dorsal raphe nucleus recruits in situ 5-HT 2A/2C receptors to modulate the post-ictal antinociception. Exp Neurol 213:410–418PubMedCrossRefGoogle Scholar
  82. Freitas RL, dos Reis Ferreira CM, Urbina MAC, Marino AU, Carvalho AD, Butera G, de Oliveira AM, Coimbra NC (2009) 5-HT 1A/1B, 5-HT 6, and 5-HT 7 serotonergic receptors recruitment in tonic-clonic seizure-induced antinociception: role of dorsal raphe nucleus. Exp Neurol 217:16–24PubMedCrossRefGoogle Scholar
  83. Freitas RL, Bolognesi LI, Twardowschy A, Corrêa FMA, Sibson NR, Coimbra NC (2013) Neuroanatomical and neuropharmacological approaches to postictal antinociception-related prosencephalic neurons: the role of muscarinic and nicotinic cholinergic receptors. Brain Behav 3:286–301PubMedPubMedCentralCrossRefGoogle Scholar
  84. Freitas RL, Oliveira RC, Oliveira R, Paschoalin-Maurin T, Aguiar Corrêa FM, Coimbra NC (2014) The role of dorsomedial and ventrolateral columns of the periaqueductal gray matter and in situ 5-HT2A and 5-HT2C serotonergic receptors in post-ictal antinociception. Synapse 68:16–30PubMedCrossRefGoogle Scholar
  85. Frixione E (2012) Pneuma–fire interactions in Hippocratic physiology. J Hist Med Allied Sci 68:505–528PubMedCrossRefGoogle Scholar
  86. Fujisaki F, Aki H, Naito A, Fukami E, Kashige N, Miake F, Sumoto K (2014) Synthesis of new 5-substituted hydantoins and symmetrical twin-drug type hydantoin derivatives. Chem Pharm Bull 62:429–438PubMedCrossRefGoogle Scholar
  87. Gagandeep DS, Mendiz E, Rao AR, Kale RK (2003) Chemopreventive effects of Cuminum cyminum in chemically induced forestomach and uterine cervix tumors in murine model systems. Nutr Cancer 47:171–180PubMedCrossRefGoogle Scholar
  88. Gautam O, Verma S, Jain S (2011) Anti convulsant and myorelaxation activity of Anacyclus pyrethrum DC.(Akarkara) root extract. Pharmacol Online 1:121–125Google Scholar
  89. Ghate NB, Chaudhuri D, Das A, Panja S, Mandal N (2015) An antioxidant extract of the insectivorous plant Drosera burmannii vahl. alleviates iron-induced oxidative stress and hepatic injury in mice. PLoS One 10:e0128221PubMedPubMedCentralCrossRefGoogle Scholar
  90. Gheita TA, Kenawy SA (2012) Effectiveness of Nigella sativa oil in the management of rheumatoid arthritis patients: a placebo controlled study. Phytother Res 26:1246–1248PubMedCrossRefGoogle Scholar
  91. Gilani A, Aziz N, Khurram I, Chaudhary K, Iqbal A (2001) Bronchodilator, spasmolytic and calcium antagonist activities of Nigella sativa seeds (Kalonji): a traditional herbal product with multiple medicinal uses. J Pak Med Assoc 51:115–120PubMedGoogle Scholar
  92. Gohari AR, Saeidnia S (2011) A review on phytochemistry of Cuminum cyminum seeds and its standards from field to market. Pharmacogn J 3:1–5CrossRefGoogle Scholar
  93. Gomes-Carneiro M, Dias DM, De-Oliveira A, Paumgartten FJ (2005) Evaluation of mutagenic and antimutagenic activities of α-bisabolol in the salmonella/microsome assay. Mutat Res Genet Toxicol Environ Mutagen 585:105–112CrossRefGoogle Scholar
  94. Goodarzi M, Duchowicz PR, Wu CH, Fernández FM, Castro EA (2009) New hybrid genetic based support vector regression as QSAR approach for analyzing flavonoids-GABA (A) complexes. J Chem Inf Model 49:1475–1485PubMedCrossRefGoogle Scholar
  95. Gören MZ, Onat F (2007) Ethosuximide: from bench to bedside. CNS Drug Rev 13:224–239PubMedPubMedCentralCrossRefGoogle Scholar
  96. Gorji A (2003) Pharmacological treatment of headache using traditional Persian medicine. Trends Pharmacol Sci 24:331–334PubMedCrossRefGoogle Scholar
  97. Goutman JD, Waxemberg MD, Doñate-Oliver F, Pomata PE, Calvo DJ (2003) Flavonoid modulation of ionic currents mediated by GABAA and GABAC receptors. Europ J Pharmacol 461:79–87CrossRefGoogle Scholar
  98. Guerrini R, Sicca F, Parmeggiani L (2003) Epilepsy and malformations of the cerebral cortex. Epileptic Disord 5:9–26Google Scholar
  99. Guieu R, Mesdjian E, Roger J, Dano P, Pouget J, Serratrice G (1992) Nociceptive threshold in patients with epilepsy. Epilepsy Res 12:57–61PubMedCrossRefGoogle Scholar
  100. Guieu R, Mesdjian E, Rochat H, Roger J (1993) Central analgesic effect of valproate in patients with epilepsy. Seizure 2:147–150PubMedCrossRefGoogle Scholar
  101. Halász P, Filakovszky J, Vargha A, Bagdy G (2002) Effect of sleep deprivation on spike-wave discharges in idiopathic generalised epilepsy: a 4× 24 h continuous long term EEG monitoring study. Epilepsy Res 51:123–132PubMedCrossRefGoogle Scholar
  102. Hanrahan JR, Chebib M, Johnston GA (2011) Flavonoid modulation of GABAA receptors. Brit J Pharmacol 163:234–245CrossRefGoogle Scholar
  103. Haruna A (2000) Depressant and anticonvulsant properties of the root decoction of Afrormosia laxiflora (Leguminosae). Phytother Res 14:57–59PubMedCrossRefGoogle Scholar
  104. Haseeb A, Asano E, Juhász C, Shah A, Sood S, Chugani HT (2007) Young patients with focal seizures may have the primary motor area for the hand in the postcentral gyrus. Epilepsy Res 76:131–139PubMedPubMedCentralCrossRefGoogle Scholar
  105. Haut SR, Bigal ME, Lipton RB (2006) Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol 5:148–157PubMedPubMedCentralCrossRefGoogle Scholar
  106. Heidari M, Dadollahi Z, Mehrabani M, Mehrabi H, Pourzadeh-Hosseini M, Behravan E, Etemad L (2009) Study of antiseizure effects of Matricaria recutita extract in mice. Ann N Y Acad Sci 1171:300–304PubMedCrossRefGoogle Scholar
  107. Hema B, Bhupendra S, Saleem TM, Gauthaman K (2009) Anticonvulsant effect of Drosera burmannii Vahl. Inter J Applied Res Nat Prod 2:1–4Google Scholar
  108. Heyman E, Levin N, Lahat E, Epstein O, Gandelman-Marton R (2014) Efficacy and safety of felbamate in children with refractory epilepsy. Eur J Paediatr Neurol 18:658–662PubMedCrossRefGoogle Scholar
  109. Hosseinzadeh H, Parvardeh S (2004) Anticonvulsant effects of thymoquinone, the major constituent of Nigella sativa seeds, in mice. Phytomed 11:56–64CrossRefGoogle Scholar
  110. Hosseinzadeh H, Talebzadeh F (2005) Anticonvulsant evaluation of safranal and crocin from Crocus sativus in mice. Fitoterap 76:722–724CrossRefGoogle Scholar
  111. Huang H-C, Syu K-Y, Lin J-K (2010) Chemical composition of Solanum nigrum linn extract and induction of autophagy by leaf water extract and its major flavonoids in AU565 breast cancer cells. J Agric Food Chem 58:8699–8708PubMedCrossRefGoogle Scholar
  112. Hule AK, Shah AS, Gambhire MN, Juvekar AR (2011) An evaluation of the antidiabetic effects of Elaeocarpus ganitrus in experimental animals. Indian J Pharm 43:56CrossRefGoogle Scholar
  113. Ilhan A, Gurel A, Armutcu F, Kamisli S, Iraz M (2005) Antiepileptogenic and antioxidant effects of Nigella sativa oil against pentylenetetrazol-induced kindling in mice. Neuropharmacol 49:456–464CrossRefGoogle Scholar
  114. Iqbal Z, Lateef M, Jabbar A, Muhammad G, Khan MN (2005) Anthelmintic activity of Calotropis procera (Ait.) Ait. F. flowers in sheep. J Ethnopharmacol 102:256–261PubMedCrossRefPubMedCentralGoogle Scholar
  115. Iranshahi M, Alizadeh M (2012) Antihyperglycemic effect of Asafoetida (Ferula assafoetida oleo-gum-resin) in streptozotocin-induced diabetic rats. World Appl Sci J 17:157–162Google Scholar
  116. Jain R, Sharma A, Gupta S, Sarethy IP, Gabrani R (2011) Solanum nigrum: current perspectives on therapeutic properties. Altern Med Rev 16:78–85Google Scholar
  117. Jayaraman R, Anitha T, Joshi VD (2010) Analgesic and anticonvulsant effects of Acorus calamus roots in mice. Int J Pharm Tech Res 2:552–555Google Scholar
  118. Jenabi E, Asle Toghiri M, Hejrati P (2012) The comparison of the effects of antiplain of valeriana officinalis risom and mefenamic acid in relief of primary dismenorrhea. Iran J Obstet Gynecol Infert 15:42–47Google Scholar
  119. Jeong JB, Jeong HJ, Park JH, Lee SH, Lee JR, Lee HK, Chung GY, Choi JD, De Lumen BO (2007) Cancer-preventive peptide lunasin from Solanum nigrum L. inhibits acetylation of core histones H3 and H4 and phosphorylation of retinoblastoma protein (Rb). J Agri Food Chem 55:10707–10713CrossRefGoogle Scholar
  120. Jiang JG, Huang XJ, Chen J (2007) Separation and purification of saponins from semen Ziziphus jujuba and their sedative and hypnotic effects. J Pharm Pharmacol 59:1175–1180PubMedCrossRefPubMedCentralGoogle Scholar
  121. Johannessen SI, Johannessen Landmark C (2010) Antiepileptic drug interactions-principles and clinical implications. Curr Neuropharmacol 8:254–267PubMedPubMedCentralCrossRefGoogle Scholar
  122. Johri R (2011) Cuminum cyminum and Carum carvi: An update. Pharmacogn Rev 5:63PubMedPubMedCentralCrossRefGoogle Scholar
  123. Juvekar M, Kulkarni M, Juvekar A (2008) Anti-stress, nootropic and anticonvulsant potential of fruit extracts of Piper longum L. Planta Med 74:PA244Google Scholar
  124. Kanner AM (2003a) Depression in epilepsy is much more than a reactive process. Epilep Curr 3:202CrossRefGoogle Scholar
  125. Kanner AM (2003b) Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry 54:388–398PubMedCrossRefPubMedCentralGoogle Scholar
  126. Kasture V, Chopde C, Deshmukh V (2000) Anticonvulsive activity of Albizzia lebbeck, Hibiscus rosa sinesis and Butea monosperma in experimental animals. J Ethnopharmacol 71:65–75PubMedCrossRefGoogle Scholar
  127. Kaur M, Goel RK (2011) Anti-convulsant activity of Boerhaavia diffusa: plausible role of calcium channel antagonism. Evid Based Complement Alternat Med 2:11–15Google Scholar
  128. Kay L, Reif PS, Belke M, Bauer S, Fründ D, Knake S, Rosenow F, Strzelczyk A (2015) Intranasal midazolam during presurgical epilepsy monitoring is well tolerated, delays seizure recurrence, and protects from generalized tonic–clonic seizures. Epilep 56:1408–1414CrossRefGoogle Scholar
  129. Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM (2009) Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev 2:135–142PubMedCrossRefPubMedCentralGoogle Scholar
  130. Ketter TA, Manji HK, Post RM (2003) Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 23:484–495PubMedCrossRefGoogle Scholar
  131. Kiasalari Z, Khalili M, Roghani M, Sadeghian A (2012) Antiepileptic and antioxidant effect of Brassica nigra on pentylenetetrazol-induced kindling in mice. Iran J Pharm Res 11:1209PubMedPubMedCentralGoogle Scholar
  132. Kiasalari Z, Khalili M, Roghani M, Heidari H, Azizi Y (2013) Antiepileptic and antioxidant effect of hydroalcoholic extract of ferula Assa foetida gum on pentylentetrazole-induced kindling in male mice. Basic Clin Neurosci 4:299PubMedPubMedCentralGoogle Scholar
  133. Kim YK, Lee DS, Lee SK, Kim S-K, Chung CK, Chang KH, Choi KY, Chung J-K, Lee MC (2003) Differential features of metabolic abnormalities between medial and lateral temporal lobe epilepsy: quantitative analysis of 18F-FDG PET using SPM. J Nucl Med 44:1006–1012PubMedPubMedCentralGoogle Scholar
  134. Krumholz A, Sung G, Fisher R, Barry E, Bergey G, Grattan L (1995) Complex partial status epilepticus accompanied by serious morbidity and mortality. Neurol 45:1499–1504CrossRefGoogle Scholar
  135. Kshirsagar N, Dalvi S, Joshi M, Sharma S, Sant H, Shah P, Chandra R (1992) Phenytoin and ayurvedic preparation–clinically important interaction in epileptic patients. 3:45–50Google Scholar
  136. Kubacka M, Librowski T, Czarnecki R, Frackowiak B, Lochynski S (2006) Anticonvulsant and antidepressant activity of the selected terpene GABA derivatives in experimental tests in mice. Pharmacol Rep 58:936PubMedPubMedCentralGoogle Scholar
  137. Kulkarni S, Dhir A (2010) An overview of curcumin in neurological disorders. Indian J Pharm Sci 72:149PubMedPubMedCentralCrossRefGoogle Scholar
  138. Kulkarni S, Joseph P (1998) Anticonvulsant profile of Siotone granules, a herbal preparation. Indian J Exper Biol 36:658–662Google Scholar
  139. Kulkarni S, Verma A (1993) Protective effect of Mentat (BR-16A) A herbal preparation, on alcohol abstinence-induced anxiety and convulsions. Indian J Exper Biol 31:435–442Google Scholar
  140. Kulkarni S, Akula KK, Dhir A (2008) Effect of Withania somnifera Dunal root extract against pentylenetetrazol seizure threshold in mice: possible involvement of GABAergic system. Indian J Exp Biol 46:465–469PubMedPubMedCentralGoogle Scholar
  141. Kumar D, Bhat ZA, Shah M (2012) Anti-anxiety activity of successive extracts of angelica archangelica linn. on the elevated t-maze and forced swimming tests in rats. J Tradit Chin Med 32:423–429PubMedCrossRefPubMedCentralGoogle Scholar
  142. Kwan P, Brodie MJ (2004) Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilep 45:1141–1149CrossRefGoogle Scholar
  143. Landmark CJ, Beiske G, Baftiu A, Burns ML, Johannessen SI (2015) Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure 28:88–91CrossRefGoogle Scholar
  144. Lanhers M-C, Fleurentin J, Mortier F, Vinche A, Younos C (1992) Anti-inflammatory and analgesic effects of an aqueous extract of Harpagophytum procumbens. Planta Med 58:117–123PubMedCrossRefPubMedCentralGoogle Scholar
  145. Lee S-J, Ko J-H, Lim K, Lim K-T (2005) 150 kDa glycoprotein isolated from Solanum nigrum Linne enhances activities of detoxicant enzymes and lowers plasmic cholesterol in mouse. Pharmacol Res 51:399–408PubMedCrossRefPubMedCentralGoogle Scholar
  146. Lee M-Y, Shin I-S, Jeon W-Y, Lim H-S, Kim J-H, Ha H (2013) Pinellia ternata Breitenbach attenuates ovalbumin-induced allergic airway inflammation and mucus secretion in a murine model of asthma. Immunopharmacol Immunotoxicol 35:410–418PubMedCrossRefPubMedCentralGoogle Scholar
  147. Leppik IE (2004) Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 13:S5–S9CrossRefGoogle Scholar
  148. Li J, Li QW, Gao DW, Han ZS, Lu WZ (2009) Antitumor and immunomodulating effects of polysaccharides isolated from Solanum nigrum Linne. Phytother Res 23:1524–1530PubMedCrossRefPubMedCentralGoogle Scholar
  149. Lin H-M, Tseng H-C, Wang C-J, Lin J-J, Lo C-W, Chou F-P (2008) Hepatoprotective effects of Solanum nigrum Linn extract against CCl4-iduced oxidative damage in rats. Chem-Biol Interact 171:283–293PubMedCrossRefPubMedCentralGoogle Scholar
  150. Liu Y-F, Gao F, Li X-W, Jia R-H, Meng X-D, Zhao R, Jing Y-Y, Wang Y, Jiang W (2012) The anticonvulsant and neuroprotective effects of baicalin on pilocarpine-induced epileptic model in rats. Neurochem Res 37:1670–1680PubMedCrossRefPubMedCentralGoogle Scholar
  151. Liu W, Ge T, Pan Z, Leng Y, Lv J, Li B (2017) The effects of herbal medicine on epilepsy. Oncotarg 8:48385Google Scholar
  152. López-Muñoz F, Ucha-Udabe R, Alamo C (2005) The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat 1:329PubMedPubMedCentralGoogle Scholar
  153. Low E, Stevenson NJ, Mathieson SR, Livingstone V, Ryan AC, Rennie JM, Boylan GB (2016) Short-term effects of phenobarbitone on electrographic seizures in neonates. Neonatol 110:40–46CrossRefGoogle Scholar
  154. Luiz N (1998) Ayurvedic drug aggravating seizures. The legal implications. Indian Pediatr 35:1144–1145PubMedGoogle Scholar
  155. Luszczki JJ, Wojda E, Andres-Mach M, Cisowski W, Glensk M, Glowniak K, Czuczwar SJ (2009) Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. Epilepsy Res 85:293–299PubMedCrossRefGoogle Scholar
  156. Łuszczki JJ, Andres-Mach M, Gleńsk M, Skalicka-Woźniak K (2010) Anticonvulsant effects of four linear furanocoumarins, bergapten, imperatorin, oxypeucedanin, and xanthotoxin, in the mouse maximal electroshock-induced seizure model: a comparative study. Pharmacol Rep 62:1231–1236PubMedCrossRefGoogle Scholar
  157. Ma Y, Yun S-R, Nam S-Y, Kim Y-B, Hong J-T, Kim Y, Choi H, Lee K, Oh K-W (2008) Protective effects of sanjoinine A against N-methyl-D-aspartate-induced seizure. Biol Pharm Bull 31:1749–1754PubMedCrossRefGoogle Scholar
  158. Madhavan V, Basnett H, Gurudeva M, Yoganarasimhan S (2009) Pharmacognostical evaluation of Drosera burmannii Vahl (Droseraceae). Indian J Tradit Knowl 8:326–333Google Scholar
  159. Madhavi A (2013) An overview of butea monosperma (Flame of Forest). World J Pharm Pharm Sci 3:307–319Google Scholar
  160. Magalhães HI, Ferreira PM, Moura ES, Torres MR, Alves AP, Pessoa OD, Costa-Lotufo LV, Moraes MO, Pessoa C (2010) In vitro and in vivo antiproliferative activity of Calotropis procera stem extracts. An Acad Bras Ciênc 82:407–416PubMedCrossRefGoogle Scholar
  161. Magiorkinis E, Sidiropoulou K, Diamantis A (2010) Hallmarks in the history of epilepsy: epilepsy in antiquity. Epilepsy Behav 17:103–108PubMedCrossRefGoogle Scholar
  162. Mahendran S, Thippeswamy B, Veerapur V, Badami S (2011) Anticonvulsant activity of embelin isolated from Embelia ribes. Phytomed 18:186–188CrossRefGoogle Scholar
  163. Mahomed IM, Ojewole JA (2006) Anticonvulsant activity of Harpagophytum procumbens DC [Pedaliaceae] secondary root aqueous extract in mice. Brain Res Bull 69:57–62PubMedCrossRefGoogle Scholar
  164. Mainasara M, Aliero B, Aliero A, Yakubu M (2012) Phytochemical and antibacterial properties of root and leaf extracts of Calotropis procera. Niger J Basic Applied Sci 20:1–6Google Scholar
  165. Makhija IK, Sharma IP, Khamar D (2010) Phytochemistry and pharmacological properties of Ficus religiosa: an overview. Ann Biol Res 1:171–180Google Scholar
  166. Mao S, Wu L, Cheng L (1994) Sedative and anticonvulsive effects of differently processed rhizoma Pinelliae. Zhongguo Zhong yao za zhi= Zhongguo zhongyao zazhi= Chin J Chinese Materia Med 218-220(256):19Google Scholar
  167. Mao S-j, Cheng L-p, Wu L-y (2001) Study on anticonvulsive effect of rhizoma Pinelliae. Zhong yao cai= Zhongyaocai= J Chin Med Materials 24:813–814Google Scholar
  168. Marder M, Paladini AC (2002) GABA (A)-receptor ligands of flavonoid structure. Curr Top Med Chem 2:853–867PubMedCrossRefPubMedCentralGoogle Scholar
  169. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW (2000) Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Libr:45–50Google Scholar
  170. Mazokopakis E, Vrentzos G, Papadakis J, Babalis D, Ganotakis E (2005) Wild chamomile (Matricaria recutita L.) mouthwashes in methotrexate-induced oral mucositis. Phytomed 12:25–27CrossRefGoogle Scholar
  171. McKay DL, Blumberg JB (2006) A review of the bioactivity and potential health benefits of peppermint tea (Mentha piperita L.). Phytother Res 20:619–633PubMedCrossRefPubMedCentralGoogle Scholar
  172. Medina JH, Viola H, Wolfman C, Marder M, Wasowski C, Calvo D, Paladini AC (1997) Overview—flavonoids: a new family of benzodiazepine receptor ligands. Neurochem Res 22:419–425PubMedCrossRefPubMedCentralGoogle Scholar
  173. Mehmood MH, Munir S, Khalid UA, Asrar M, Gilani AH (2015) Antidiarrhoeal, antisecretory and antispasmodic activities of Matricaria chamomilla are mediated predominantly through K+-channels activation. BMC Complement Altern Med 15:75PubMedPubMedCentralCrossRefGoogle Scholar
  174. Meldrum BS, Rogawski MA (2007) Molecular targets for antiepileptic drug development. Neurotherapeut 4:18–61CrossRefGoogle Scholar
  175. Mishra RK, Singh SK (2009) Reversible antifertility effect of aqueous rhizome extract of Curcuma longa L. in male laboratory mice. Contraception 79:479–487PubMedCrossRefGoogle Scholar
  176. Mishra A, Verma S, Mishra AP (2012) A plant review: Butea monosperma (Lam.) Kuntze. Res J Pharm Biol Chem Sci 3:700–714Google Scholar
  177. Mishra S, Aeri V, Gaur PK, Jachak SM (2014) Phytochemical, therapeutic, and ethnopharmacological overview for a traditionally important herb: Boerhavia diffusa Linn. BioMed Res Int 3:20–24Google Scholar
  178. Mncwangi N, Chen W, Vermaak I, Viljoen AM, Gericke N (2012) Devil’s claw—A review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbens. J Ethnopharmacol 143:755–771PubMedCrossRefGoogle Scholar
  179. Monforte M, Trovato A, Rossitto A, Forestieri A, d’Aquino A, Miceli N, Galati E (2002) Anticonvulsant and sedative effects of Salvadora persica L. stem extracts. Phytother Res 16:395–397PubMedCrossRefGoogle Scholar
  180. Mossa J, Tariq M, Mohsin A, Ageel A, Al-Yahya M, Al-Said M, Rafatullah S (1991) Pharmacological studies on aerial parts of Calotropis procera. Amer J Chin Med 19:223–231CrossRefGoogle Scholar
  181. Moussard C, Alber D, Toubin M-M, Thevenon N, Henry J-C (1992) A drug used in traditional medicine, Harpagophytum procumbens: no evidence for NSAID-like effect on whole blood eicosanoid production in human. Prostagland Leukotrien Essent Fat Acids 46:283–286CrossRefGoogle Scholar
  182. Mula M, Monaco F (2002) Carbamazepine–risperidone interactions in patients with epilepsy. Clin Neuropharmacol 25:97–100PubMedCrossRefGoogle Scholar
  183. N Aboul-Enein M, A El-Azzouny A, A Saleh O, A Maklad Y (2012) On chemical structures with potent antiepileptic/anticonvulsant profile. Mini Rev Med Chem 12:671–700CrossRefGoogle Scholar
  184. Naderi F, Javadi SA, Motamedi M, Sahraian MA (2012) The efficacy of primidone in reducing severe cerebellar tremors in patients with multiple sclerosis. Clin Neuropharmacol 35:224–226PubMedCrossRefGoogle Scholar
  185. Neamati A, Chaman F, Hosseini M, Boskabady MH (2014) The effects of Valeriana officinalis L. hydro-alcoholic extract on depression like behavior in ovalbumin sensitized rats. J Pharm Bioallied Sci 6:97PubMedPubMedCentralGoogle Scholar
  186. Nikoletopoulou V, Papandreou M, Tavernarakis N (2015) Autophagy in the physiology and pathology of the central nervous system. Cell Death Differ 22:398PubMedCrossRefGoogle Scholar
  187. Niquet J, Suchomelova L, Thompson K, Klitgaard H, Matagne A, Wasterlain C (2017) Acute and long-term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticus. Epilep 3:45–50Google Scholar
  188. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K (2005) Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 53:959–963PubMedCrossRefGoogle Scholar
  189. Nogueira E, Vassilieff V (2000) Hypnotic, anticonvulsant and muscle relaxant effects of Rubus brasiliensis. Involvement of GABA A-system. J Ethnopharmacol 70:275–280PubMedCrossRefGoogle Scholar
  190. Nsuala BN, Enslin G, Viljoen A (2015) “Wild cannabis”: A review of the traditional use and phytochemistry of Leonotis leonurus. J Ethnopharmacol 174:520–539PubMedCrossRefGoogle Scholar
  191. Occhiuto F, Pino A, Palumbo DR, Samperi S, Pasquale R, Sturlese E, Circosta C (2009) Relaxing effects of Valeriana officinalis extracts on isolated human non-pregnant uterine muscle. J Pharm Pharmacol 61:251–256PubMedCrossRefGoogle Scholar
  192. Ojewole J (2005) Antinociceptive, antiinflammatory and antidiabetic effects of Leonotis leonurus (L.) R. BR.(Lamiaceae) leaf aqueous extract in mice and rats. Methods Findings Exp Clin Pharmacol 27:257–264CrossRefGoogle Scholar
  193. Okoye TC, Akah PA, Omeje EO, Okoye FB, Nworu CS (2013) Anticonvulsant effect of kaurenoic acid isolated from the root bark of Annona senegalensis. Pharmacol Biochem Behav 109:38–43PubMedCrossRefGoogle Scholar
  194. Olaleye MT, Akinmoladun AC, Ogunboye AA, Akindahunsi AA (2010) Antioxidant activity and hepatoprotective property of leaf extracts of Boerhaavia diffusa Linn against acetaminophen-induced liver damage in rats. Food Chem Toxicol 48:2200–2205PubMedCrossRefGoogle Scholar
  195. Orellana-Paucar AM, Serruys A-SK, Afrikanova T, Maes J, De Borggraeve W, Alen J, León-Tamariz F, Wilches-Arizábala IM, Crawford AD, de Witte PA (2012) Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in zebrafish and mouse seizure models. Epilepsy Behav 24:14–22PubMedCrossRefGoogle Scholar
  196. Oyedemi S, Yakubu M, Afolayan A (2011) Antidiabetic activities of aqueous leaves extract of Leonotis leonurus in streptozotocin induced diabetic rats. J Med Plant Res 5:119–125Google Scholar
  197. Pahuja M, Mehla J, Reeta K, Joshi S, Gupta YK (2011) Hydroalcoholic extract of Zizyphus jujuba ameliorates seizures, oxidative stress, and cognitive impairment in experimental models of epilepsy in rats. Epilepsy Behav 21:356–363PubMedCrossRefGoogle Scholar
  198. Pahuja M, Kleekal T, Reeta K, Tripathi M, Gupta YK (2012a) Interaction profile of Zizyphus jujuba with phenytoin, phenobarbitone, and carbamazepine in maximal electroshock-induced seizures in rats. Epilepsy Behav 25:368–373PubMedCrossRefGoogle Scholar
  199. Pahuja M, Mehla J, Reeta K, Joshi S, Gupta YK (2012b) Root extract of Anacyclus pyrethrum ameliorates seizures, seizure-induced oxidative stress and cognitive impairment in experimental animals. Epilepsy Res 98:157–165PubMedCrossRefGoogle Scholar
  200. Panda S, Jafri M, Kar A, Meheta B (2009) Thyroid inhibitory, antiperoxidative and hypoglycemic effects of stigmasterol isolated from Butea monosperma. Fitoterap 80:123–126CrossRefGoogle Scholar
  201. Pandit R, Phadke A, Jagtap A (2010) Antidiabetic effect of Ficus religiosa extract in streptozotocin-induced diabetic rats. J Ethnopharmacol 128:462–466PubMedCrossRefGoogle Scholar
  202. Parasuraman S, Thing GS, Dhanaraj SA (2014) Polyherbal formulation: concept of ayurveda. Pharmacogn Rev 8:73PubMedPubMedCentralCrossRefGoogle Scholar
  203. Pari L, Amarnath Satheesh M (2004) Antidiabetic effect of Boerhavia diffusa: effect on serum and tissue lipids in experimental diabetes. J Med Food 7:472–476PubMedCrossRefGoogle Scholar
  204. Parnas I, Rashkovan G, Ravin R, Fischer Y (2000) Novel mechanism for presynaptic inhibition: GABAAReceptors affect the release machinery. J Neurophysiol 84:1240–1246PubMedCrossRefGoogle Scholar
  205. Patel D, Kumar R, Prasad S, Hemalatha S (2011) Pharmacologically screened aphrodisiac plant-A review of current scientific literature. Asian Pac J Trop Biomed 1:S131–S138CrossRefGoogle Scholar
  206. Pathak S, Wanjari M, Jain S, Tripathi M (2010) Evaluation of antiseizure activity of essential oil from roots of Angelica archangelica Linn. in mice. Indian J Pharm Sci 72:371PubMedPubMedCentralCrossRefGoogle Scholar
  207. Patil MS, Patil C, Patil S, Jadhav R (2011) Anticonvulsant activity of aqueous root extract of Ficus religiosa. J Ethnopharmacol 133:92–96PubMedCrossRefGoogle Scholar
  208. Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P (2006) Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res 20:683–686PubMedCrossRefGoogle Scholar
  209. Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P (2009) Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients. Phytother Res 23:1281–1286PubMedCrossRefGoogle Scholar
  210. Pei YQ (1983) A review of pharmacology and clinical use of piperine and its derivatives. Epilep 24:177–182CrossRefGoogle Scholar
  211. Peng W-H, Hsieh M-T, Lee Y-S, Lin Y-C, Liao J (2000) Anxiolytic effect of seed of Ziziphus jujuba in mouse models of anxiety. J Ethnopharmacol 72:435–441PubMedCrossRefGoogle Scholar
  212. Pérez-Saad H, Buznego MT (2008) Behavioral and antiepileptic effects of acute administration of the extract of the plant Cestrum nocturnum Lin (lady of the night). Epilepsy Behav 12:366–372PubMedCrossRefGoogle Scholar
  213. Pickerd N, Gale K, Hartley L, Gibbon F, te WaterNaude J (2014) G340 (P) Ethosuximide retention in children with epilepsy. Arch Dis Child 99:A140–A140CrossRefGoogle Scholar
  214. Pieretti S, Di Giannuario A, Capasso A, Nicoletti M (1992) Pharmacological effects of phenylpropanoid glycosides from Orobanche hederae. Phytother Res 6:89–93CrossRefGoogle Scholar
  215. Pillai J, Sperling MR (2006) Interictal EEG and the diagnosis of epilepsy. Epilep 47:14–22CrossRefGoogle Scholar
  216. Post RM, Ketter TA, Uhde T, Ballenger JC (2007) Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness. CNS Drugs 21:47–71PubMedCrossRefGoogle Scholar
  217. Poureshghi F, Ghandforoushan P, Safarnejad A, Soltani S (2017) Interaction of an antiepileptic drug, lamotrigine with human serum albumin (HSA): application of spectroscopic techniques and molecular modeling methods. J Photochem Photobiol B Biol 166:187–192CrossRefGoogle Scholar
  218. Pourgholami M, Majzoob S, Javadi M, Kamalinejad M, Fanaee G, Sayyah M (1999) The fruit essential oil of Pimpinella anisum exerts anticonvulsant effects in mice. J Ethnopharmacol 66:211–215PubMedCrossRefGoogle Scholar
  219. Preux P-M, Druet-Cabanac M (2005) Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol 4:21–31PubMedCrossRefGoogle Scholar
  220. Radhakrishnan K, Pandian J, Santhoshkumar T, Thomas S, Deetha T, Sarma P, Jayachandran D, Mohamed E (2000) Prevalence, knowledge, attitude, and practice of epilepsy in Kerala, South India. Epilep 41:1027–1035CrossRefGoogle Scholar
  221. Rahmatullah M, Mollik MAH, Islam MK, Islam MR, Jahan FI, Khatun Z, Seraj S, Chowdhury MH, Islam F, Miajee Z (2010) A survey of medicinal and functional food plants used by the folk medicinal practitioners of three villages in Sreepur Upazilla, Magura district, Bangladesh. Amer Eurasian J Sustainable Agri 4:363–373Google Scholar
  222. Rajagopal RR (2013) Investigation of in-vitro anthelmintic activity of ethanolic leaf extract of Boerhavia diffusa (Nyctaginaceae) including pharmacognostical and phytochemical screening. J Pharm Res 7:774–780Google Scholar
  223. Raju A, Christina AJM, Murali A (2012) Antitumor activity of ethanol and aqueous extracts of Drosera burmannii vahl. In: EAC bearing mice. Spatula DD-Tamamlayıcı Tıp ve İlaç Geliştirme Alanında Hakemli Dergi, vol 2, pp 83–88Google Scholar
  224. Rani S, Kaushik V, Saini V, Nain P, Rani D (2013) Biological studies of Anacyclus pyrethrum. Amer J Pharm Res 3:45–50Google Scholar
  225. Ravi V, Saleem TM, Patel S, Raamamurthy J, Gauthaman K (2009) Anti-inflammatory effect of methanolic extract of Solanum nigrum Linn berries. Inter J Applied Res Nat Products 2:33–36Google Scholar
  226. Rawat A, Mehrotra S, Tripathi S, Shome U (1997) Hepatoprotective activity of Boerhaavia diffusa L. roots—a popular Indian ethnomedicine. J Ethnopharmacol 56:61–66PubMedCrossRefGoogle Scholar
  227. Raza M, Shaheen F, Choudhary M, Sombati S, Rafiq A, Suria A, DeLorenzo R (2001) Anticonvulsant activities of ethanolic extract and aqueous fraction isolated from Delphinium denudatum. J Ethnopharmacol 78:73–78PubMedCrossRefGoogle Scholar
  228. Raza M, Alghasham AA, Alorainy MS, El-Hadiyah TM (2008) Potentiation of valproate-induced anticonvulsant response by Nigella sativa seed constituents: the role of GABA receptors. Inter J Health Sci 2:15Google Scholar
  229. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 89:1358–1367PubMedCrossRefGoogle Scholar
  230. Rezvani ME, Roohbakhsh A, Allahtavakoli M, Shamsizadeh A (2010) Anticonvulsant effect of aqueous extract of Valeriana officinalis in amygdala-kindled rats: possible involvement of adenosine. J Ethnopharmacol 127:313–318PubMedCrossRefGoogle Scholar
  231. Rosenberg G (2007) The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 64:2090–2103PubMedCrossRefGoogle Scholar
  232. Safaralie A, Fatemi S, Sefidkon F (2008) Essential oil composition of Valeriana officinalis L. roots cultivated in Iran: comparative analysis between supercritical CO2 extraction and hydrodistillation. J Chromatogr 1180:159–164CrossRefGoogle Scholar
  233. Sakat S, Wankhede S, Juvekar A, Mali V, Bodhankar S (2009) Antihypertensive effect of aqueous extract of Elaeocarpus ganitrus Roxb. seeds in renal artery occluded hypertensive rats. Inter J PharmTech Res 1:779–782Google Scholar
  234. Salami M, Safarnejad A, Hamidi H (2007) Effect of salinity stress on morphological characters of Cuminum cyminum and Valeriana officinalis. Pajouhesh and Sazandegi. Pajouhesh Sazandegi 72:77–83Google Scholar
  235. Sankari M, Chitra V, Silambujanaki P, Raju D (2010) Anticonvulsant activity of ethanolic extract of Aegle marmelos (leaves) in mice. Inter J PharmTech Res 2:640–643Google Scholar
  236. Sarma JK, Bhuyan G (2004) An experimental evaluation of the effect of rudraksha (Elaeocarpus ganitrus roxb) in adrenaline and nicotine induced hypertension. Anc Sci Life 23:1PubMedPubMedCentralGoogle Scholar
  237. Sayyah M, Mahboubi A, Kamalinejad M (2002a) Anticonvulsant effect of the fruit essential oil of Cuminum cyminum in mice. Pharm Biol 40:478–480CrossRefGoogle Scholar
  238. Sayyah M, Valizadeh J, Kamalinejad M (2002b) Anticonvulsant activity of the leaf essential oil of Laurus nobilis against pentylenetetrazole-and maximal electroshock-induced seizures. Phytomed 9:212–216CrossRefGoogle Scholar
  239. Sayyah M, Nadjafnia L, Kamalinejad M (2004) Anticonvulsant activity and chemical composition of Artemisia dracunculus L. essential oil. J Ethnopharmacol 94:283–287PubMedCrossRefGoogle Scholar
  240. Sayyah M, Khodaparast A, Yazdi A, Sardari S (2011) Screening of the anticonvulsant activity of some plants from Fabaceae family in experimental seizure models in mice. DARU: J Faculty Pharm, Tehran Uni Med Sci 19:301Google Scholar
  241. Schachter SC (2008) Complementary and alternative medical therapies. Curr Opin Neurol 21:184–189PubMedCrossRefPubMedCentralGoogle Scholar
  242. Schaller B, Rüegg SJ (2003) Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilep 44:1223–1232CrossRefGoogle Scholar
  243. Selles C, Dib MEA, Djabou N, Beddou F, Muselli A, Tabti B, Costa J, Hammouti B (2013) Antimicrobial activity and evolution of the composition of essential oil from Algerian Anacyclus pyrethrum L. through the vegetative cycle. Nat Prod Res 27:2231–2234PubMedCrossRefPubMedCentralGoogle Scholar
  244. Shah PA, Shapoo SF, Koul RK, Khan MA (2009) Prevalence of epilepsy in school-going children (6-18 years) in Kashmir Valley of North-West India. J Indian Med Assoc 107:216–218PubMedPubMedCentralGoogle Scholar
  245. Shah G, Singh PS, Mann A, Shri R (2011) Scientific basis for the chemical constituent and therapeutic use of Elaeocarpus species: a review. Inter J Institutional Pharm Life Sci 1:267–278Google Scholar
  246. Sharifzadeh M, Hadjiakhoondi A, Khanavi M, Susanabadi M (2006) Preclinical study: effects of aqueous, methanolic and chloroform extracts of rhizome and aerial parts of Valeriana officinalis L. on naloxone-induced jumping in morphine-dependent mice. Addict Biol 11:145–151PubMedCrossRefPubMedCentralGoogle Scholar
  247. Sharma N, Garg V (2009) Antidiabetic and antioxidant potential of ethanolic extract of Butea monosperma leaves in alloxan-induced diabetic mice. Indian J Biochem Biophys 46:99–105PubMedPubMedCentralGoogle Scholar
  248. Sharma V, Thakur M, Chauhan NS, Dixit VK (2008) Evaluation of the anabolic, aphrodisiac and reproductive activity of Anacyclus pyrethrum DC in male rats. Sci Pharm 77:97–110CrossRefGoogle Scholar
  249. Sharma J, Gairola S, Gaur R, Painuli R, Siddiqi T (2013) Ethnomedicinal plants used for treating epilepsy by indigenous communities of sub-Himalayan region of Uttarakhand, India. J Ethnopharmacol 150:353–370PubMedCrossRefPubMedCentralGoogle Scholar
  250. Shin J-W, Chu K, Jung K-H, Lee S-T, Moon J, Lee SK (2014) Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations. Int J Clin Pharmacol Ther 52:1017–1022PubMedCrossRefGoogle Scholar
  251. Shivakumar S, Suresh H, Hallikeri C, Hatapakki B, Handiganur J, Sankh K, Shivakumar B (2009) Anticonvulsant effect of Cyperus rotundus Linn rhizomes in rats. J Nat Remed 9:192–196Google Scholar
  252. Shukia B, Khanna N, Godhwani J (1987) Effect of Brahmi Rasayan on the central nervous system. J Ethnopharmacol 21:65–74PubMedCrossRefPubMedCentralGoogle Scholar
  253. Sidiropoulou K, Diamantis A, Magiorkinis E (2010) Hallmarks in 18th-and 19th-century epilepsy research. Epilepsy Behav 18:151–161PubMedCrossRefPubMedCentralGoogle Scholar
  254. Silbergeld EK, Miller LP, Kennedy S, Eng N (1979) Lead, GABA, and seizures: effects of subencephalopathic lead exposure on seizure sensitivity and GABAergic function. Environ Res 19:371–382PubMedCrossRefPubMedCentralGoogle Scholar
  255. Sills GJ (2005) Not another gabapentin mechanism! Epilep Curr 5:75CrossRefGoogle Scholar
  256. Singh D, Goel RK (2009) Anticonvulsant effect of Ficus religiosa: role of serotonergic pathways. J Ethnopharmacol 123:330–334PubMedCrossRefPubMedCentralGoogle Scholar
  257. Singh B, Chopra A, Ishar M, Sharma A, Raj T (2010a) Pharmacognostic and antifungal investigations of Elaeocarpus ganitrus (Rudrakasha). Indian J Pharm Sci 72:261PubMedPubMedCentralCrossRefGoogle Scholar
  258. Singh I, Singh M, Singh T, Bijjem K-RV, Kalia AN (2010b) Anticonvulsant potential of Anisomeles malabarica leaves against experimentally induced convulsions in rats. Inter J Green Pharm 4:45–50Google Scholar
  259. Singh D, Singh B, Goel RK (2011a) Traditional uses, phytochemistry and pharmacology of Ficus religiosa: A review. J Ethnopharmacol 134:565–583PubMedCrossRefPubMedCentralGoogle Scholar
  260. Singh R, Mehta A, Mehta P, Shukla K (2011b) Anthelmintic activity of rhizome extracts of Curcuma longa and Zingiber officinale (Zingiberaceae). Inter J Pharm Pharm Sci 3:236–237Google Scholar
  261. Singh P, Singh D, Goel RK (2014) Ficus religiosa L. figs—a potential herbal adjuvant to phenytoin for improved management of epilepsy and associated behavioral comorbidities. Epilepsy Behav 41:171–178PubMedCrossRefPubMedCentralGoogle Scholar
  262. Solomonia R, Kuchiashvili N, Berulava A, Pkhakadze V, Trapaidze N, Zhvania M, Abesadze I, Kojima H, Dalakishvili N (2004) Purification and identification of components of the Aquilegia vulgaris extract fraction exhibiting anti-epileptic activity. J Biol Phys Chem 4:187–192Google Scholar
  263. Soman S, Korah P, Jayanarayanan S, Mathew J, Paulose C (2012) Oxidative stress induced NMDA receptor alteration leads to spatial memory deficits in temporal lobe epilepsy: ameliorative effects of Withania somnifera and Withanolide A. Neurochem Res 37:1915–1927PubMedCrossRefPubMedCentralGoogle Scholar
  264. Soman S, Anju T, Jayanarayanan S, Antony S, Paulose C (2013) Impaired motor learning attributed to altered AMPA receptor function in the cerebellum of rats with temporal lobe epilepsy: ameliorating effects of Withania somnifera and withanolide A. Epilepsy Behav 27:484–491PubMedCrossRefPubMedCentralGoogle Scholar
  265. Sotaniemi E, Rautio A, Backstrom M, Arvela P, Pelkonen O (1995) CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Brit J Clin Pharmacol 39:71–76CrossRefGoogle Scholar
  266. Srivsatava R, Srivastava SP, Jaiswal N, Mishra A, Maurya R, Srivastava AK (2011) Antidiabetic and antidyslipidemic activities of Cuminum cyminum L. in validated animal models. Med Chem Res 20:1656–1666CrossRefGoogle Scholar
  267. Stafford GI, Pedersen ME, van Staden J, Jäger AK (2008) Review on plants with CNS-effects used in traditional South African medicine against mental diseases. J Ethnopharmacol 119:513–537PubMedCrossRefPubMedCentralGoogle Scholar
  268. Stefan H, Feuerstein T (2007) Novel anticonvulsant drugs. Pharmacol Ther 113:165–183PubMedCrossRefPubMedCentralGoogle Scholar
  269. Sucher NJ, Carles MC (2015) A pharmacological basis of herbal medicines for epilepsy. Epilep Behav 52:308–318CrossRefGoogle Scholar
  270. Sun DA, Sombati S, DeLorenzo RJ (2001) Glutamate injury–induced Epileptogenesis in hippocampal neurons: an in vitro model of stroke-induced “epilepsy”. Stroke 32:2344–2350PubMedCrossRefPubMedCentralGoogle Scholar
  271. Sun Y-X, Tang Y, Wu A-L, Liu T, Dai X-L, Zheng Q-S, Wang Z-B (2010) Neuroprotective effect of liquiritin against focal cerebral ischemia/reperfusion in mice via its antioxidant and antiapoptosis properties. J Asian Nat Prod Res 12:1051–1060PubMedCrossRefPubMedCentralGoogle Scholar
  272. Tacchini M, Spagnoletti A, Marieschi M, Caligiani A, Bruni R, Efferth T, Sacchetti G, Guerrini A (2015) Phytochemical profile and bioactivity of traditional ayurvedic decoctions and hydro-alcoholic macerations of Boerhaavia diffusa L. and Curculigo orchioides Gaertn. Nat Prod Res 29:2071–2079PubMedCrossRefPubMedCentralGoogle Scholar
  273. Tandon V, Gupta R (2005) An experimental evaluation of anticonvulsant activity of Vitex-negundo. Indian J Physiol Pharmacol 49:199PubMedPubMedCentralGoogle Scholar
  274. Tao K, Wang X (2016) The comorbidity of epilepsy and depression: diagnosis and treatment. Expert Rev Neurother 16:1321–1333PubMedCrossRefGoogle Scholar
  275. Temkin NR (2001) Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilep 42:515–524CrossRefGoogle Scholar
  276. Toda S, Miyase T, Arichi H, Tanizawa H, Takino Y (1985) Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L. Chem Pharm Bull 33:1725–1728PubMedCrossRefGoogle Scholar
  277. Tomson T, Battino D, Perucca E (2016) Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol 15:210–218PubMedCrossRefGoogle Scholar
  278. Trinka E, Höfler J, Zerbs A (2012) Causes of status epilepticus. Epilep 53:127–138CrossRefGoogle Scholar
  279. Tudur Smith C, Marson A, Williamson P (2001) Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev (4):45–48Google Scholar
  280. Van Donselaar CA, Stroink H, Arts WF (2006) How confident are we of the diagnosis of epilepsy? Epilep 47:9–13CrossRefGoogle Scholar
  281. Vattanajun A, Watanabe H, Tantisira MH, Tantisira B (2005) Isobolographically additive anticonvulsant activity between Centella asiatica’s ethyl acetate fraction and some antiepileptic drugs. J Med Assoc Thail 88:131–140Google Scholar
  282. Vespa PM, Miller C, McArthur D, Eliseo M, Etchepare M, Hirt D, Glenn TC, Martin N, Hovda D (2007) Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med 35:2830PubMedPubMedCentralCrossRefGoogle Scholar
  283. Vyawahare N, Bodhankar S (2009) Anticonvulsant activity of Argyreia speciosa in mice. Indian J Pharm Sci 71:131PubMedPubMedCentralCrossRefGoogle Scholar
  284. Wang F, Xu Z, Ren L, Tsang SY, Xue H (2008) GABA A receptor subtype selectivity underlying selective anxiolytic effect of baicalin. Neuropharmacol 55:1231–1237CrossRefGoogle Scholar
  285. Wang K-L, Hsia S-M, Chan C-J, Chang F-Y, Huang C-Y, Bau D-T, Wang PS (2013) Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells. Expert Opin Ther Targets 17:337–349PubMedCrossRefPubMedCentralGoogle Scholar
  286. Wannang NN, Anuka JA, Kwanashie HO, Gyang S, Auta A (2008) Anti-seizure activity of the aqueous leaf extract of Solanum nigrum linn (solanaceae) in experimental animals. Afr Health Sci 8:45–50Google Scholar
  287. Witt JA, Elger C, Helmstaedter C (2013) Impaired verbal fluency under topiramate–evidence for synergistic negative effects of epilepsy, topiramate, and polytherapy. Eur J Neurol 20:130–137PubMedCrossRefPubMedCentralGoogle Scholar
  288. Wu S, Sun A, Liu R (2005) Separation and purification of baicalin and wogonoside from the Chinese medicinal plant Scutellaria baicalensis Georgi by high-speed counter-current chromatography. J Chromatogr A 1066:243–247PubMedCrossRefPubMedCentralGoogle Scholar
  289. Wu H, Li J, Fronczek FR, Ferreira D, Burandt CL, Setola V, Roth BL, Zjawiony JK (2013) Labdane diterpenoids from Leonotis leonurus. Phytochem 91:229–235CrossRefGoogle Scholar
  290. Wu Y, Liu D, Song Z (2015) Neuronal networks and energy bursts in epilepsy. Neurosci 287:175–186CrossRefGoogle Scholar
  291. Yazdi A, Sardari S, Sayyah M, Ezzati MH (2011) Evaluation of the anticonvulsant activity of the leaves of Glycyrrhiza glabra var. glandulifera grown in Iran, as a possible renewable source for anticonvulsant compounds. Iran J Pharm Res 10:75PubMedPubMedCentralGoogle Scholar
  292. Yemitan O, Salahdeen H (2005) Neurosedative and muscle relaxant activities of aqueous extract of Bryophyllum pinnatum. Fitoterap 76:187–193CrossRefGoogle Scholar
  293. Yue GG, Chan BC, Hon P-M, Lee MY, Fung K-P, Leung P-C, Lau CB (2010) Evaluation of in vitro anti-proliferative and immunomodulatory activities of compounds isolated from Curcuma longa. Food Chem Toxicol 48:2011–2020PubMedPubMedCentralCrossRefGoogle Scholar
  294. Zakaria ZA, Gopalan HK, Zainal H, Pojan NHM, Morsid NA, Aris A, Sulaiman MR (2006) Antinociceptive, anti-inflammatory and antipyretic effects of Solanum nigrum chloroform extract in animal models. Yakuhaku Zasshi 126:1171–1178CrossRefGoogle Scholar
  295. Zeng L-h, Zhang H-d, Xu C-j, Bian Y-j, Xu X-j, Xie Q-m, Zhang R-h (2013) Neuroprotective effects of flavonoids extracted from licorice on kainate-induced seizure in mice through their antioxidant properties. J Zhejiang Uni Sci B 14:1004–1012CrossRefGoogle Scholar
  296. Zhang B, McDaniel SS, Rensing NR, Wong M (2013) Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One 8:e57445PubMedPubMedCentralCrossRefGoogle Scholar
  297. Zhang Y, Lian Y, Xie N (2017) Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report. Med 96:e9273CrossRefGoogle Scholar
  298. Zhu HL, Wan JB, Wang YT, Li BC, Xiang C, He J, Li P (2014) Medicinal compounds with antiepileptic/anticonvulsant activities. Epilep 55:3–16CrossRefGoogle Scholar

via Awareness and current knowledge of epilepsy | SpringerLink

, , , , ,

Leave a comment

[ARTICLE] Εvaluation of machine learning methods for seizure prediction in epilepsy – Full Text PDF

Abstract:

Epilepsy affects about 50 million people worldwide of which one third is refractory to medication. An automated and reliable system that warns of impending seizures would greatly improve patient’s quality of life by overcoming the uncertainty and helplessness due to the unpredicted events. Here we present new seizure prediction results including a performance comparison of different methods. The analysis is based on a new set of intracranial EEG data that has been recorded in our working group during presurgical evaluation.
We applied two different methods for seizure prediction and evaluated their performance pseudoprospectively. The comparison of this evaluation with common statistical evaluation reveals possible reasons for overly optimistic estimations of the performance of seizure forecasting systems.

1 Introduction

Affecting about 1 % of the world population, epilepsy is one of the most common neurological diseases. Although seizures cover relatively short periods in a patient’s life, the uncertainty when the next seizure will occur can produce a high level of anxiety [4]. For 70 % of the patients, medication can reduce the frequency of seizures or even abolish them. However, patients report that unwanted side effects of the medication as well as the unpredictability of seizures are the severest handicaps of this disease [13]. A mobile system with the ability to predict seizures can help to relief the patients’ anxiety related to the uncertainty of events by enabling them to seek shelter, apply a short acting drug or inform the treating physician about the event. The device might also be used to prevent or mitigate the seizure [12].

Usually, seizure prediction is treated as a binary classification problem of brain activity, recorded as intracranial electroencephalography (icEEG) [8], with the state of impending seizures (preictal) being labeled as 1 and periods with a big temporal distance to the next seizure (interictal) labeled as 0. In this contribution, we present a new database that has been recorded in our working group. By intensifying the cooperation of clinical research and data analysis we minimize loss of descriptive metadata. For feature extraction and classification of the recorded icEEG signals we employed both, a recently proposed deep convolutional neural network and a featurebased method.

[…]

Full Texy PGF

, , , ,

Leave a comment

[WEB PAGE] Identification and management of depression in people with epilepsy to save lives

Depression is the most common psychiatric comorbidity in people with epilepsy. Clinical studies have found that 20% to 30% of people with epilepsy have depression; the incidence may be as high as 50% to 55% in people visiting hospital epilepsy centers.

Untreated depression is associated with lower quality of life, poor treatment adherence, higher health care utilization and a risk for suicide up to 30 times higher than average.

Yet in most people with epilepsy, depression goes undetected. As an example, a Texas study conducted depression screening on 192 consecutive people visiting a high-volume epilepsy clinic. More than 1 in 4 people-;26%-;screened positive for depression and were subsequently diagnosed with depression. Of them, 65% had no previous history of the condition.

At the 33rd International Epilepsy Congress in Bangkok in June 2019, several sessions focused on psychiatric comorbidities in people with epilepsy and the crucial role of epileptologists in their identification and management.

Sometimes we think too much about the epileptology and not enough about comorbidities. There is individual clinician variation in this area. We must each recognize our own competency and know what we don’t know. Those are strongly influenced by our training, coworkers, culture, country and interests. But in the end, all clinicians must meet a minimum standard.”

Mike Kerr (UK), co-chair of a session on neuropsychiatric issues in epilepsy

This minimum standard was established by ILAE as part of its new epileptology curriculum. Domain 6 includes competencies and learning objectives about comorbidities, including the following:

6.1.1 Recognize psychiatric comorbidities, such as depression, anxiety, ADHD, psychosis and autism spectrum disorder

6.1.2 Appropriately manage or advise regarding psychiatric comorbidities

6.1.3 Adjust anti-seizure treatment as required by psychiatric comorbidities

However, the gap between knowledge and practice remains relatively wide. In a Bangkok session on psychological and psychiatric learning objectives in the ILAE curriculum, an informal survey found that most audience members did not conduct depression or suicidality screening in their clinics.

“Up to half of your patients will have depression and up to half will have anxiety,” said W. Curt LaFrance, Jr. (USA). “But almost no one in this session is using a depression screening tool.”

Generally, neurologists cite several reasons for not using screening tools or asking their patients about depression, including time constraints and the perception that screening is not their role. But physicians who manage the care of people with epilepsy are uniquely positioned to identify depression and initiate treatment that can improve quality of life and seizure control.

“It is part of our clinical responsibility as neurologists and epileptologists to take action in response to the high depression rates in people with epilepsy,” said Rosa Michaelis (Germany), co-chair of one of the sessions. “We should not expect other physicians to take over this task.”

Depression assessment: Individual variation

There’s no single “right” way for epileptologists to handle depression assessment and management, said Kerr. “Some people are multitaskers and will take on psychiatric management,” he said. “At the other end will be people who feel that none of it is their job. In the middle are the guiders, who keep epilepsy as a focus but also address the psychiatric issues.

Michaelis suggested that standardized screening is the most realistic strategy to increase detection rates. “We cannot rely on self-reported symptoms,” she said. Patients may not volunteer information about how they are feeling unless they are asked directly-;and even then, they may deny or downplay their symptoms, or physicians may misinterpret their complaints. Screening tools provide valuable information in only a few minutes; they also can be a gateway to conversations about depression and suicidality.

If the idea of establishing a formal screening program is overwhelming, Kerr suggested being alert to the possibility of depression in every patient and merely asking one question: “During the last month, have you felt down, depressed, or hopeless, or had little interest or pleasure in doing things?”

If the answer sounds at all like “Yes,” refer the patient to a mental health professional. Alternatively, he said, “If you feel competent in mental health assessment, consider using a validated measure” to get a better idea of the extent and severity of the patient’s issue.

For screening, Kerr and others in Bangkok recommended the Neurological Disorders and Depression Inventory in Epilepsy (NDDI-E), which is free for public use and available in more than a dozen languages. The NDDI-E consists of six short “feeling” statements:

  • Everything is a struggle
  • Nothing I do is right
  • Feel guilty
  • I’d be better off dead
  • Frustrated
  • Difficulty finding pleasure

For each statement, the person indicates how often they felt that way over the past two weeks. Points are given for each answer: always or often (4 points); sometimes (3); rarely (2); never (1).

A cutoff of 15 points is generally used to suggest depression, though cutoffs of 11 to 16 have been reported. According to Kerr, a cutoff score of 15 has 81% sensitivity and 90% specificity.

The Patient Health Questionnaire-9 (PHQ-9) or a shorter form, the PHQ-2, also can be administered.

The ILAE Commission on Psychiatry recommends annual screening, but many of the experts urged more frequent screening. They noted that because depression can be episodic, more frequent screening will better identify those patients in need of treatment. It also may improve patient-physician communication and trust.

Though the ILAE consensus statement does not include a recommendation for anxiety screening, Kerr urged clinicians to screen for anxiety as well. The NDDI-E screens for both depression and anxiety; Kerr also recommended the GAD-2 or the ET7, short questionnaires that have been tested in people with epilepsy. Patients with positive screens can be referred to a mental health specialist or assessed further.

“All clinicians should aim to identify depression and anxiety,” Kerr said. “To be a level-2 epileptologist by ILAE standards, you will have to know how to do this.”

Antidepressants: Myth and reality

Psychotherapy and medication are common treatments for depression. Though few studies have focused on the effectiveness of psychotherapy for depression specifically in people with epilepsy, dozens of trials and several meta-analyses support the use of cognitive behavioral therapy (CBT).

Some medical professionals may avoid prescribing antidepressants to people with epilepsy because they believe these drugs decrease the seizure threshold. There is little scientific basis for this, say experts.

A 2017 study followed adults with epilepsy six months before and after the initiation of antidepressant therapy with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norephinephrine reuptake inhibitors (SNRIs). Though the study was relatively small (N=84), the findings showed that antidepressants did not increase seizure frequency. In fact, among patients having more than one seizure per month at baseline, 27.5% went on to have less than 1 per month, and 48% had at least a 50% reduction in frequency. Of the patients, 73% had a therapeutic response to the antidepressant; changes in seizure frequency were independent of therapeutic response.

Pediatric screening

Janelle Wagner (USA) and Avani Modi (USA) addressed the issue of screening for depression and anxiety in the pediatric epilepsy population as it relates to two learning objectives in the ILAE curriculum:

  • 2.5.1 – Recognize when to refer patients for a higher level of care (as it relates to psychiatric comorbidities)
  • 2.9.1 – Provide counseling specific to children with epilepsy and their parents, according to the epilepsy types

Children with epilepsy are at higher risk than other children for depression, anxiety and attention deficit disorder, said Kette Valente (Brazil). Among children with epilepsy, 1 in 4 has depression, 1 in 4 has anxiety, and between 15% and 27% consider committing suicide.

A 2015 ILAE survey found that 55% of pediatric neurologists screened for these comorbidities, compared with only 7% in 2005. However, 50% of clinicians did not feel comfortable with their knowledge of anxiety, and only 40% said that screening for and managing comorbidities were priorities.

Depressive symptoms in children can look different than in adults, said Modi. Low self-esteem, cognitive symptoms, and negative thinking are common. Irritability and disruptive behavior also may be concerns, she said. “What may be seen as a conduct problem is actually depression.”

Valente, Wagner, and Modi described multiple screening instruments that take between 10 and 30 minutes to complete. Valente noted, however, that the instruments are often completed by parents, who do not always reflect their child’s behavior accurately.

The NDDI-E-Y, the pediatric version of the NDDI-E, had a sensitivity of 79% and a specificity of 92% in a 2016 validation study. Like the NDDI-E, the youth version can alert providers to suicidal ideation and provide a platform to discuss it.

Valente suggested screening children at their first visit, and then at certain time points:

  • Every 6 months
  • When seizures worsen
  • After medication changes
  • After any type of complaint about mood or behavior, whether it comes from the child or a parent or teacher

“Screening is not perfect, but it must be done,” she said. “There is no reason not to do it.”

Suicidality – what to do?

Jakob Christensen (Denmark) warned congress attendees that suicide risk overall is increasing worldwide, and that people with epilepsy have triple the risk of a suicide attempt and at least double the risk of death by suicide, compared with the general population. People with psychiatric comorbidities, and those recently diagnosed with epilepsy, are at even greater risk.

A recent meta-analysis found a prevalence of suicidal ideation of 23.2% among people with epilepsy-;more than 7 times the prevalence in the general population. The pooled event rate of completed suicide in the meta-analysis was 0.5%, more than 30 times higher than the global estimated suicide rate (0.016%).

Screening can reveal suicidal thoughts or plans; on the NDDI-E, this can be seen on item 4, “I’d be better off dead”. A score of 3 or 4 on this item has been shown to identify suicidality with 84% sensitivity and 91% specificity.

Christensen recommended asking every patient about suicidal thoughts. “It can be as simple as saying, ‘Do you ever feel like life isn’t worth living?’ he said. Asking the question will not increase the risk of suicidality, he said. “People who have these thoughts are actually quite happy to have you ask the question. They often don’t realize that suicidality can be associated with epilepsy.”

If NDDI-E results indicate suicidality, Milena Gandy (Australia) outlined next steps:

  • Ask the patient if they’ve thought about harming themselves in the past week. If they say yes, ask for details. Ask if they’ve ever tried to kill themselves and if so, how and when.
  • If you feel they may be in imminent danger of harming themselves, ask if they can guarantee their safety until you see them again.
  • If they ask for immediate help or can’t guarantee their safety, you can call a suicide hotline for them, refer them to the emergency room (or escort them there yourself), or refer them to a crisis service.
  • If they are not in immediate crisis, refer them for mental health support if they don’t already have it. If they do have it, talk with them about making an urgent appointment.

The clock is ticking

Screening and conversations do take time. And while all physicians are pressed for time, “We need to think creatively about how we can do what’s possible” with screening, said Markus Reuber (UK). For example, ensure that any patient information (brochures, videos, other handouts) includes mention of mood disorders and anxiety as common comorbidities.

Reuber also noted that some offices and centers have epilepsy nurses or community health advocates who can talk about mental health, and mental health services, with patients. Providers must find creative ways to make time for these issues, he said, as they are a crucial part of epilepsy treatment.

“We can draw on experiences from other health conditions,” said Modi. “In cancer care, chronic pain and heart disease, referring to a psychologist is common practice. Yet there are still some perceptions in neurological disorders that psychological care isn’t as important. But improving mental health can improve medical care.”

 

via Identification and management of depression in people with epilepsy to save lives

, , , , ,

Leave a comment

[ARTICLE] Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience – Full Text

Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (BRV) are pyrrolidone derivate compounds binding at the presynaptic SV2A receptor site and are thus representative of AEDs with a unique mode of action. LEV was extensively investigated in randomized controlled trials and has a very promising efficacy both in focal and generalized epilepsies. Its pharmacokinetic profile is favorable and LEV does not undergo clinically relevant interactions. Adverse reactions comprise mainly asthenia, somnolence, and behavioral symptoms. It has now been established as a first-line antiepileptic drug. BRV has been recently introduced as an adjunct antiepileptic drug in focal epilepsy with a similarly promising pharmacokinetic profile and possibly increased tolerability concerning psychiatric adverse events. This review summarizes the essential preclinical and clinical data of LEV and BRV that is currently available and includes the experiences at a large tertiary referral epilepsy center.

Since the introduction of bromides as the first effective antiepileptic drugs (AEDs),1 chronic AED treatment that consisted of the sustained prevention of epileptic seizures has remained the standard of epilepsy therapy.2 Before to the introduction of the newer generation of AEDs, a limited number of drugs were available that addressed the blockade of sodium channels, acting on gamma-aminobutyric acid (GABA) type A receptors, or interacting with calcium channels as the leading modes of action.3 With the introduction of the newer AEDs a heterogeneous group of drugs appeared, some of them offering new mechanisms of action2 including the blockade of GABA aminotransferase (vigabatrin [VGB]), GABA re-uptake from the synaptic cleft (tiagabine [TGB]), the modulation of calcium channels (gabapentin [GBP], pregabalin [PGB]), the selective non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolproprionic acid (AMPA) receptor antagonism (perampanel [PER]), and the binding to the presynaptic SV2A receptor site which is the unique mode of action of levetiracetam (LEV) and brivaracetam (BRV), the AEDs this review will cover. The authors will summarize the development of both compounds as derivatives of piracetam, review the currently available preclinical and clinical data, and discuss the question of whether BRV has the potential to be recognized as being superior to LEV and if it can replace it as the standard AED with the main mode of action both AEDs reflect.[…]

 

Continue —-> Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience – Bernhard J. Steinhoff, Anke M. Staack, 2019

, , , , , , ,

Leave a comment

[Abstract] No prevention or cure of epilepsy as yet – Invited review

Highlights

  • Approximately 20% of all epilepsy is caused by acute acquired injury such as traumatic brain injury, stroke and CNS infection, with potential to prevent epilepsy
  • No treatment to prevent acquired epilepsy exists; and very few clinical studies have been done during the last 15 years to develop such treatment
  • We review possible reasons for this, possible ways to rectify the situations and note some of the ways currently under way to do so
  • We further review “cures” of epilepsy that occur spontaneously, and after surgical and sometimes medical antiseizure treatments. We note the limited understanding of the mechanisms of such remissions and thus, at present inability to replicate them with targeted therapy

Abstract

Approximately 20% of all epilepsy is caused by acute acquired injury such as traumatic brain injury, stroke and CNS infection. The known onset of the injury which triggers the epileptogenic process, early presentation to medical care, and a latency between the injury and the development of clinical epilepsy present an opportunity to intervene with treatment to prevent epilepsy. No such treatment exists and yet there has been remarkably little clinical research during the last 20 years to try to develop such treatment. We review possible reasons for this, possible ways to rectify the situations and note some of the ways currently under way to do so.

Resective surgical treatment can achieve “cure” in some patients but is sparsely utilized. In certain “self-limiting” syndromes of childhood and adolescence epilepsy remits spontaneously. In a proportion of patients who become seizure free on medications or with dietary treatment, seizure freedom persists when treatment is discontinued. We discuss these situations which can be considered “cures”; and note that at present we have little understanding of mechanism of such cures, and cannot therefore translate them into a treatment paradigm targeting a “cure” of epilepsy.

via No prevention or cure of epilepsy as yet – ScienceDirect

, , , , , , , , , ,

Leave a comment

[Abstract] Unintended pregnancy, prenatal care, newborn outcomes, and breastfeeding in women with epilepsy.

Abstract

Objective To compare the proportions of unintended pregnancies, prenatal vitamin or folic acid (PNVF) use, adequate prenatal care visits, and breastfeeding among women with epilepsy (WWE) to women without epilepsy (WWoE).

 

Methods The Pregnancy Risk Assessment Monitoring System (PRAMS) is an annual survey of randomly sampled postpartum women administered by the Centers for Disease Control and Prevention. We used PRAMS data from 13 states from 2009 to 2014 to compare the primary outcomes in WWE and WWoE, as well as our secondary outcomes of contraception practices, newborn outcomes, and time to recognition of pregnancy. We adjusted for maternal age, race, ethnicity, and socioeconomic status (SES), and we calculated odds ratios for these outcomes using logistic regression.

 

Results This analysis included 73,619 women, of whom 541 (0.7%) reported epilepsy, representing 3,442,128 WWoE and 26,635 WWE through weighted sampling. In WWE, 55% of pregnancies were unintended compared to 48% in WWoE. After adjustment for covariates, epilepsy was not associated with unintended pregnancy or with inadequate prenatal care. WWE were less likely to report breastfeeding but more likely to report daily PNVF use. Newborns of WWE had higher rates of prematurity.

 

Conclusions Although planning for pregnancy is of utmost importance for WWE, more than half the pregnancies in WWE were unintended. Maternal age and SES differences likely contribute to the higher rates in WWE compared to WWoE. The proportion of women reporting breastfeeding is lower in WWE despite studies indicating the safety of breastfeeding in WWE.

 

via Unintended pregnancy, prenatal care, newborn outcomes, and breastfeeding in women with epilepsy | Neurology

, , , , , , , ,

Leave a comment

[BLOG POST] Mozart and epilepsy: the rhythm beats on

 

I can’t seem to get away from the theme of Mozart and epilepsy. When I first looked at this, in a blog post titled Mozart and seizures? The links between epilepsy and music, I took the topic rather lightly, more a subscript than a headline you may say. But I have since learnt to take the links between epilepsy and music more seriously.

By Barbara Krafft – The Bridgeman Art Library, Object 574471, Public Domain, Link

 

The major trigger for my ‘road to Damascus’ conversion is a 2018 paper titled Study of the Mozart effect in children with epileptic electroencephalograms, published in the journal Seizure. The paper was an eye-opener because it gave a very helpful comprehensive context to the broader beneficial effect of music…not just in epilepsy, but in other neurological disorders such as Parkinson’s diseasedementia and sleep disordersThe authors, Elyza Grylls and colleagues, started on the established premise that Mozart’s music has a beneficial effect on epilepsy. What they wanted to know was if other forms of music have a similar settling effect on epilepsy, or if only Mozart’s music carries the magic touch. The authors therefore played Mozart’s Sonata for two pianos in D major (K448) to 40 children with epilepsy who were undergoing an EEG (electroencephalogram, or electrical brain wave test). They then compared this with the effect of playing other types of music. Remarkably, they found that only Mozart’s Sonata led to a significant reduction in EEG epileptic discharges.

Public Domain, Link

The authors concluded that there was indeed an anti-epileptic effect of Mozart’s music, the so-called  ‘Mozart therapy’. But what is so special about K448? They speculate that it has to do with the structure of Mozart’s music, containing as it does, long periodicities. Interestingly, the music of Yanni, which is similarly structured, has somewhat a similar effect on brain wave activity. On the contrary, and sorry to Beethoven fans, Fur Elise doesn’t have this effect.

By W.J. Baker (held the expired copyright on the photograph) – Library of Congress[1]Contrairement à une erreur fréquemment répandue le buste a été réalisé par Hugo Hagen, non pas à partir du masque mortuaire mais, comme de nombreux autres, d’après le masque réalisé en 1812 par Franz Klein pour un buste qu’il devait réaliser ensuite., Public Domain, Link

So what does the structure of Mozart’s music do to the brain? One suggestion is that Mozart’s music enhances the body’s parasympathetic drive; this reduces the heart rate, and thereby inhibits the brain’s propensity to epileptic seizures. The suppression of this parasympathetic drive is of course the theory behind using vagus nerve stimulation (VNS) to treat drug-resistant epilepsy. For more on VNS, see my previous blog, Vagus nerve stimulation: from neurology and beyond!

By Bionerd – MRI at Charite Mitte, Berlin (used with permission), CC BY 3.0Link

You have surely wondered by now if K448 is the only one of Mozart’s compositions to have an anti-epileptic effect. It doesn’t matter if you have not, because the authors of another interesting paper did. They titled their study, published in 2018, Mozart’s music in children with drug-refractory epileptic encephalopathies: comparison of two protocols. Published in the journal Epilepsy and Behaviour, the authors, Giangennaro Coppola and colleagues, compared the effect of K448 with a set of his other compositions. Intriguingly they found that the composition set actually had a greater effect in epilepsy than K448…by a wide margin of 70% to 20%! Furthermore, the set was better tolerated by the children; they were less irritable and had a better nighttime sleep quality.   

https://www.publicdomainpictures.net/en/view-image.php?image=76907&picture=dog-amp-child-painting

It therefore appears as if it all rosy in the garden of music and the brain. But it is not! As every rose grows on a thorny tree, so do some forms of music trigger epileptic seizures. This so-called musicogenic epilepsy is well-recognised, and two recent culprits are the music of Sean Paul, discussed in the journal Scientific American , and the music of Ne Yo, explored by NME. Therefore you should craft your playlist wisely.

By CLASSICNEYO – Own workCC BY-SA 4.0Link

So, is it time for neurologists to start prescribing music?

Or is it too much of a double-edged sword?

Music is #SimplyIrresistible. Luca Florio on Flickr. https://www.flickr.com/photos/elle_florio/29516744480

via Mozart and epilepsy: the rhythm beats on – The Neurology Lounge

, , , , , , , , , , , ,

Leave a comment

[VIDEO] What’s, Why’s and How’s of the Vagus Nerve Stimulator

Dr Nemechek Discusses the Vagus Nerve Stimulator, how it’s used and what it can do for a patient.

, , , , ,

Leave a comment

[EDITORIAL] Reducing birth defects in women with epilepsy – Neurology

Merely 20 years ago, a report of the Quality Standards Subcommittee of the American Academy of Neurology recommended that antiepileptic drug (AED) selection for pregnant women with epilepsy should be based on the AED “deemed most appropriate for her seizure type.”1 Scientifically, lumping all AEDs together when chemical structures and mechanisms of action differ greatly was questionable, but the evidence for differential effects on fetal outcomes was sparse. Multiple research studies have now made it clear that the level of risk for major congenital malformation (MCMs) differs substantially among AEDs. The prevalence of MCMs is highest with valproate monotherapy2,3 compared to other monotherapies, and includes neural tube defects, heart malformations, cleft palate, hypospadias, and polydactyly. Likewise, the prevalence of MCMs is higher in polytherapy combinations that include valproate, compared to polytherapies that exclude valproate. MCM rates with some AED monotherapies even approximate the rates in the general population (e.g., levetiracetam, lamotrigine).2,3

via Reducing birth defects in women with epilepsy | Neurology

, , , , , , ,

Leave a comment

[Abstract + References] Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy

Abstract

Cannabidiol (CBD) is a major active component of the Cannabis plant, which, unlike tetrahydrocannabinol (THC), is devoid of euphoria-inducing properties. During the last 10 years, there has been increasing interest in the use of CBD-enriched products for the treatment of epilepsy. In 2018, an oil-based highly purified liquid formulation of CBD (Epidiolex) derived from Cannabis sativa was approved by the US Food and Drug Administration for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The mechanisms underlying the antiseizure effects of CBD are unclear but may involve, among others, antagonism of G protein-coupled receptor 55 (GPR55), desensitization of transient receptor potential of vanilloid type 1 (TRPV1) channels, and inhibition of adenosine reuptake. CBD has complex and variable pharmacokinetics, with a prominent first-pass effect and a low oral bioavailability that increases fourfold when CBD is taken with a high-fat/high-calorie meal. In four randomized, double-blind, parallel-group, adjunctive-therapy trials, CBD given at doses of 10 and 20 mg/kg/day administered in two divided administrations was found to be superior to placebo in reducing the frequency of drop seizures in patients with LGS and convulsive seizures in patients with DS. Preliminary results from a recently completed controlled trial indicate that efficacy also extends to the treatment of seizures associated with the tuberous sclerosis complex. The most common adverse events that differentiated CBD from placebo in controlled trials included somnolence/sedation, decreased appetite, increases in transaminases, and diarrhea, behavioral changes, skin rashes, fatigue, and sleep disturbances. About one-half of the patients included in the DS and LGS trials were receiving concomitant therapy with clobazam, and in these patients a CBD-induced increase in serum levels of the active metabolite norclobazam may have contributed to improved seizure outcomes and to precipitation of some adverse effects, particularly somnolence.

References

  1. 1.
    Russo EB. Cannabis and epilepsy: an ancient treatment returns to the fore. Epilepsy Behav. 2017;70(Pt B):292–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Friedman D, Sirven JI. Historical perspective on the medical use of cannabis for epilepsy: ancient times to the 1980s. Epilepsy Behav. 2017;70(Pt B):298–301.CrossRefPubMedGoogle Scholar
  3. 3.
    O’Shaughnessy WB. On the preparations of the Indian hemp, or Gunjah (Cannabis indica): their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Prov Med J Retrosp Med Sci. 1843;5:363–9.PubMedCentralGoogle Scholar
  4. 4.
    Gowers W. Epilepsy and other chronic convulsive disorders. London: Churchill; 1881.Google Scholar
  5. 5.
    Reynolds JR. On some of the therapeutical uses of Indian hemp. Arch Med. 1868;2:154–60.Google Scholar
  6. 6.
    McMeens RR. Cannabis indica in convulsions. West Lancet 1856:327–31.Google Scholar
  7. 7.
    Carlini EA, Leite JR, Tannhauser M, Berardi AC. Letter: Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol. 1973;25(8):664–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Consroe P, Wolkin A. Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther. 1977;201(1):26–32.PubMedGoogle Scholar
  9. 9.
    Izquierdo I, Orsingher OA, Berardi AC. Effect of cannabidiol and of other cannabis sativa compounds on hippocampal seizure discharges. Psychopharmacologia. 1973;28(1):95–102.CrossRefPubMedGoogle Scholar
  10. 10.
    Karler R, Cely W, Turkanis SA. The anticonvulsant activity of cannabidiol and cannabinol. Life Sci. 1973;13(11):1527–31.CrossRefPubMedGoogle Scholar
  11. 11.
    Leite JR, Carlini EA, Lander N, Mechoulam R. Anticonvulsant effects of the (−) and (+)isomers of cannabidiol and their dimethylheptyl homologs. Pharmacology. 1982;24(3):141–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017;7(2):61–76.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55(6):783–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Epidiolex. Full Prescribing Information. https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf. Accessed 30 Jan 2019.
  15. 15.
    GWPharmaceuticals. Press release: GW Pharmaceuticals reports positive Phase 3 pivotal trial results for EPIDIOLEX (cannabidiol) oral solution in patients with seizures associated with tuberous sclerosis complex. Carlsbad, USA, May 6, 2019 http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-reports-positive-phase-3-pivotal-trial. Accessed 25 June 2019.
  16. 16.
    Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol. 1982;83(3–4):293–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Klein BD, Jacobson CA, Metcalf CS, Smith MD, Wilcox KS, Hampson AJ, et al. Evaluation of cannabidiol in animal seizure models by the Epilepsy Therapy Screening Program (ETSP). Neurochem Res. 2017;42(7):1939–48.CrossRefPubMedGoogle Scholar
  18. 18.
    Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, et al. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia. 2019;60(2):303–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569–77.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Karler R, Turkanis SA. Cannabis and epilepsy. Adv Biosci. 1978;22–23:619–41.PubMedGoogle Scholar
  21. 21.
    Karler R, Turkanis SA. The cannabinoids as potential antiepileptics. J Clin Pharmacol. 1981;21(S1):437S–48S.CrossRefPubMedGoogle Scholar
  22. 22.
    Gobira PH, Vilela LR, Goncalves BD, Santos RP, de Oliveira AC, Vieira LB, et al. Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: possible role of the mTOR pathway and reduction in glutamate release. Neurotoxicology. 2015;50:116–21.CrossRefPubMedGoogle Scholar
  23. 23.
    Do Val-da Silva RA, Peixoto-Santos JE, Kandratavicius L, De Ross JB, Esteves I, De Martinis BS, et al. Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy. Front Pharmacol. 2017;8:131.Google Scholar
  24. 24.
    Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21(5):344–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Chiu P, Olsen DM, Borys HK, Karler R, Turkanis SA. The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia. 1979;20(4):365–75.CrossRefPubMedGoogle Scholar
  26. 26.
    Turkanis SA, Smiley KA, Borys HK, Olsen DM, Karler R. An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats. Epilepsia. 1979;20(4):351–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav. 2017;70(Pt B):319–27.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kaplan JS, Stella N, Catterall WA, Westenbroek RE. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA. 2017;114(42):11229–34.CrossRefPubMedGoogle Scholar
  29. 29.
    Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia. 2018;59(10):1842-66.Google Scholar
  30. 30.
    Reddy DS, Golub VM. The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther. 2016;357(1):45–55.CrossRefPubMedGoogle Scholar
  31. 31.
    Katona I. Cannabis and endocannabinoid signaling in epilepsy. Handb Exp Pharmacol. 2015;231:285–316.CrossRefPubMedGoogle Scholar
  32. 32.
    Blair RE, Deshpande LS, DeLorenzo RJ. Cannabinoids: is there a potential treatment role in epilepsy? Expert Opin Pharmacother. 2015;16(13):1911–4.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Di Marzo V, De Petrocellis L, Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol. 2005;168:147–85.CrossRefGoogle Scholar
  34. 34.
    Friedman D, French JA, Maccarrone M. Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. Lancet Neurol. 2019;18(5):504–12.CrossRefPubMedGoogle Scholar
  35. 35.
    Lupica CRHY, Devinsky O, Hoffman AF. Cannabinoids as hippocampal network administrators. Neuropharmacology. 2017;124:25–37.CrossRefPubMedGoogle Scholar
  36. 36.
    Soltesz I, Alger BE, Kano M, Lee SH, Lovinger DM, Ohno-Shosaku T, et al. Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy. Nat Rev Neurosci. 2015;16(5):264–77.CrossRefPubMedGoogle Scholar
  37. 37.
    Ledgerwood CJ, Greenwood SM, Brett RR, Pratt JA, Bushell TJ. Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways. Br J Pharmacol. 2011;162(1):286–94.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hofmann ME, Frazier CJ. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention. Exp Neurol. 2013;244:43–50.CrossRefPubMedGoogle Scholar
  39. 39.
    Goffin K, Van Paesschen W, Van Laere K. In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain. 2011;134(Pt 4):1033–40.CrossRefPubMedGoogle Scholar
  40. 40.
    Ludanyi A, Eross L, Czirjak S, Vajda J, Halasz P, Watanabe M, et al. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci. 2008;28(12):2976–90.CrossRefPubMedGoogle Scholar
  41. 41.
    Magloczky Z, Toth K, Karlocai R, Nagy S, Eross L, Czirjak S, et al. Dynamic changes of CB1-receptor expression in hippocampi of epileptic mice and humans. Epilepsia. 2010;51(Suppl 3):115–20.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, et al. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010;51(5):768–72.CrossRefPubMedGoogle Scholar
  43. 43.
    Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70(Pt B):313–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Nichol K, Stott C, Jones N, Bazelot M, Whalley BJ. The proposed multimodal mechanism of action of cannabidiol in epilepsy: Modulation of intracellular calcium and adenosine-mediated signaling. [abstract] American Epilepsy Society Annual Meeting, New Orleans, LA, November 30–December 4, 2018. https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/554059. Accessed 12 Feb 2019.
  45. 45.
    Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–805.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol. 2019;176(10):1455–69.CrossRefPubMedGoogle Scholar
  47. 47.
    Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613–23.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134(4):845–52.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA. 2006;103(20):7895–900.CrossRefPubMedGoogle Scholar
  50. 50.
    De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479–94.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Gaston TE, Szaflarski JP. Cannabis for the treatment of epilepsy: an update. Curr Neurol Neurosci Rep. 2018;18(11):73.CrossRefPubMedGoogle Scholar
  52. 52.
    Aso E, Fernandez-Duenas V, Lopez-Cano M, Taura J, Watanabe M, Ferrer I, et al. Adenosine A2A-cannabinoid CB1 receptor heteromers in the hippocampus: cannabidiol blunts Δ(9)-tetrahydrocannabinol-induced cognitive impairment. Mol Neurobiol. 2019. [Epub ahead of print].Google Scholar
  53. 53.
    Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791–802.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Hill AJ, Jones NA, Smith I, Hill CL, Williams CM, Stephens GJ, et al. Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. Neurosci Lett. 2014;566:269–74.CrossRefPubMedGoogle Scholar
  55. 55.
    Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014;5(11):1131–41.CrossRefPubMedGoogle Scholar
  56. 56.
    Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12(4):699–730.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Leo A, Russo E, Elia M. Cannabidiol and epilepsy: Rationale and therapeutic potential. Pharmacol Res. 2016;107:85–92.CrossRefPubMedGoogle Scholar
  58. 58.
    McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Δ(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172(3):737–53.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Peres FF, Lima AC, Hallak JEC, Crippa JA, Silva RH, Abilio VC. Cannabidiol as a promising strategy to treat and prevent movement disorders? Front Pharmacol. 2018;9:482.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Rong C, Lee Y, Carmona NE, Cha DS, Ragguett RM, Rosenblat JD, et al. Cannabidiol in medical marijuana: research vistas and potential opportunities. Pharmacol Res. 2017;121:213–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Thompson CH, Kearney JA. Cannabidiol mellows out resurgent sodium current. Epilepsy Curr. 2016;16(6):399–401.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Bouron A. Phyto and endocannabinoids exert complex actions on calcium and zinc signaling in mouse cortical neurons. Biochem Pharmacol. 2018;152:244–51.CrossRefPubMedGoogle Scholar
  63. 63.
    Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci. 2019;11:487.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Vilela LR, Lima IV, Kunsch EB, Pinto HPP, de Miranda AS, Vieira ELM, et al. Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels. Epilepsy Behav. 2017;75:29–35.CrossRefPubMedGoogle Scholar
  65. 65.
    Pandolfo P, Silveirinha V, dos Santos-Rodrigues A, Venance L, Ledent C, Takahashi RN, et al. Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. Eur J Pharmacol. 2011;655(1–3):38–45.CrossRefPubMedGoogle Scholar
  66. 66.
    Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018;293(43):16546–58.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Watkins AR. Cannabinoid interactions with ion channels and receptors. Channels (Austin). 2019;13(1):162–7.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Millar SA, Stone NL, Yates AS, O’Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053–67.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–60.CrossRefPubMedGoogle Scholar
  71. 71.
    Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski M, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019. [Epub ahead of print].Google Scholar
  72. 72.
    Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89(5–6):165–70.CrossRefPubMedGoogle Scholar
  73. 73.
    Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, et al. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009;37(7):1496–504.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Zendulka O, Dovrtelova G, Noskova K, Turjap M, Sulcova A, Hanus L, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab. 2016;17(3):206–26.CrossRefPubMedGoogle Scholar
  75. 75.
    Morrison G, Crockett J, Blakey G, Sommerville K. A Phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019. [Epub ahead of print].Google Scholar
  76. 76.
    Whalley BJ, Stott C, Gray RA, N.A. J. The human metabolite of cannabidiol, 7-hydroxy-cannabidiol, but not 7-carboxy-cannabidiol, is anticonvulsant in the maximal electroshock threshold test (MEST) in mouse [abstract]. American Epilepsy Society Annual Meeting, December 1-5, 2017, Washington, DC. https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/381222. Accessed 09 Feb 2019.
  77. 77.
    Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204–11.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Wheless JW, Dlugos D, Miller I, Oh DA, Parikh N, Phillips S, et al. Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol in pediatric patients with treatment-resistant epilepsy. CNS Drugs. 2019;33(6):593–604.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Taylor L, Crockett J, Tayo B, Morrison G. A phase 1, open-label, parallel-group, single-dose trial of the pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment. J Clin Pharmacol. 2019. [Epub ahead of print].Google Scholar
  80. 80.
    Stott C, White L, Wright S, Wilbraham D, Guy G. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus. 2013;2(1):236.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Sativex. Orosomucosal Spray, Summary of Product Characteristics, 28 August 2018 revision. https://www.medicines.org.uk/emc/product/602/smpc#DOCREVISION. Accessed 11 Feb 2019.
  82. 82.
    Arellano AL, Papaseit E, Romaguera A, Torrens M, Farre M. Neuropsychiatric and general interactions of natural and synthetic cannabinoids with drugs of abuse and medicines. CNS Neurol Disord Drug Targets. 2017;16(5):554–66.CrossRefPubMedGoogle Scholar
  83. 83.
    Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86–95.CrossRefPubMedGoogle Scholar
  85. 85.
    Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011;39(11):2049–56.CrossRefPubMedGoogle Scholar
  86. 86.
    Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88(15–16):730–6.CrossRefPubMedGoogle Scholar
  87. 87.
    Morrison G, Taylor L, Crockett J, Critchley D, Tayo B. A Phase 1 investigation into the potential effects of cannabidiol on CYP3A4-mediated drug-drug interactions in healthy volunteers [abstract]. American Epilepsy Society Annual Meeting, New Orleans, LA, November 30–December 4, 2018. https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/500033. Accessed 09 Feb 2019.
  88. 88.
    Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888–97.CrossRefPubMedGoogle Scholar
  89. 89.
    Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2015;373(11):1048–58.CrossRefPubMedGoogle Scholar
  90. 90.
    Friedman D, Cilio MR, Tilton N, Sullivan J, Hedlund J, Rosenberg E, et al. The effect of epidiolex (cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program [abstract]. American Epilepsy Society 2014 annual meeting. Seattle, WA, December 5–9, 2014. https://www.aesnet.org/annual_meeting/abstract_search#/sortDate_na_dt/DESC/0/epidiolex/?Year=2014. Accessed 09 Feb 2019.
  91. 91.
    Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586–92.CrossRefPubMedGoogle Scholar
  92. 92.
    Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–51.CrossRefPubMedGoogle Scholar
  93. 93.
    Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34(4):608–11.CrossRefPubMedGoogle Scholar
  94. 94.
    Diacomit. Summary of Product Characteristics, revised 8 January 2014, European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/diacomit-epar-product-information_en.pdf. Accessed 06 Mar 2019.
  95. 95.
    Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Effects of cannabidiol on brivaracetam plasma levels. Epilepsia. 2019;60(7):e74–7.CrossRefPubMedGoogle Scholar
  96. 96.
    Tayo B, Ben-Menachem E, Gunning B, Arenas Cabrera CM, Crockett J, Taylor L, et al. Exploration of the potential for plasma protein binding displacement and drug–drug interactions of valproate in combination with cannabidiol [abstract]. American Epilepsy Society Annual Meeting, New Orleans, LA, November 30–December 4, 2018. https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/540271. Accessed 09 Feb 2019.
  97. 97.
    Grayson L, Vines B, Nichol K, Szaflarski JP. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 2018;9:10–1.CrossRefPubMedGoogle Scholar
  98. 98.
    Al Saabi A, Allorge D, Sauvage FL, Tournel G, Gaulier JM, Marquet P, et al. Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metab Dispos. 2013;41(3):568–74.CrossRefPubMedGoogle Scholar
  99. 99.
    Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27(1):19–27.CrossRefPubMedGoogle Scholar
  100. 100.
    Niesink RJ, van Laar MW. Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry. 2013;4:130.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 1998;63(1):1–6.CrossRefGoogle Scholar
  102. 102.
    Todd SM, Arnold JC. Neural correlates of interactions between cannabidiol and Δ(9)-tetrahydrocannabinol in mice: implications for medical cannabis. Br J Pharmacol. 2016;173(1):53–65.CrossRefPubMedGoogle Scholar
  103. 103.
    Todd SM, Zhou C, Clarke DJ, Chohan TW, Bahceci D, Arnold JC. Interactions between cannabidiol and Δ(9)-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway. Eur Neuropsychopharmacol. 2017;27(2):132–45.CrossRefPubMedGoogle Scholar
  104. 104.
    Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–20.CrossRefPubMedGoogle Scholar
  105. 105.
    Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–8.CrossRefPubMedGoogle Scholar
  106. 106.
    Ahn Y, Drummond-Main C, Kiroski I, Rho JM. Cannabidiol impairs mitochondrial function independent of CB1 and GPR55 receptors [abstract]. American Epilepsy Society Annual Meeting, New Orleans, LA, November 30–December 4, 2018. https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/500201. Accessed 10 Feb 2019.
  107. 107.
    Ahn Y, Drummond-Main C, Yee NC, Kim DY, Rho JM. Effects of cannabidiol on mitochondrial bioenergetics and homeostasis [abstract]. American Epilepsy Society Annual Meeting, New Orleans, LA, November 30–December 4, 2018. https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/344542. Accessed 10 Feb 2019.
  108. 108.
    Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741–53.CrossRefPubMedGoogle Scholar
  109. 109.
    McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, et al. A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol. 2018;5(9):1077–88.CrossRefPubMedPubMedCentralGoogle Scholar
  110. 110.
    Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(10):1617–24.CrossRefPubMedGoogle Scholar
  111. 111.
    Kaplan EH, Offermann EA, Sievers JW, Comi AM. Cannabidiol treatment for refractory seizures in Sturge–Weber syndrome. Pediatr Neurol. 2017;71(18–23):e2.Google Scholar
  112. 112.
    Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, et al. Cannabidiol as a potential treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017;32(1):35–40.CrossRefPubMedGoogle Scholar
  113. 113.
    Saade D, Joshi C. Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report. Pediatr Neurol. 2015;52(5):544–7.CrossRefPubMedGoogle Scholar
  114. 114.
    Dale T, Downs J, Olson H, Bergin AM, Smith S, Leonard H. Cannabis for refractory epilepsy in children: a review focusing on CDKL5 Deficiency Disorder. Epilepsy Res. 2019;151:31–9.CrossRefPubMedGoogle Scholar
  115. 115.
    Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131–7.CrossRefPubMedGoogle Scholar
  116. 116.
    Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, et al. Cannabis-based products for pediatric epilepsy: a systematic review. Epilepsia. 2019;60(1):6–19.CrossRefPubMedGoogle Scholar
  117. 117.
    Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;9:759.CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118.
    Pamplona FA, da Silva LR, Coan AC. Corrigendum: Potential clinical benefits of CBD-rich Cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;9:1050.CrossRefPubMedGoogle Scholar
  119. 119.
    White CM. A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacol. 2019. [Epub ahead of print].Google Scholar
  120. 120.
    FDA. United States of America, 2016. Warning letters and test results for cannabidiol-related products. https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm484109.htm. Accessed 17 Feb 2019.
  121. 121.
    Bettiol A, Lombardi N, Crescioli G, Maggini V, Gallo E, Mugelli A, et al. Galenic preparations of therapeutic Cannabis sativa differ in cannabinoids concentration: a quantitative analysis of variability and possible clinical implications. Front Pharmacol. 2019;9:1543.CrossRefPubMedPubMedCentralGoogle Scholar
  122. 122.
    Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of Cannabidiol extracts sold online. JAMA. 2017;318(17):1708–9.CrossRefPubMedPubMedCentralGoogle Scholar
  123. 123.
    Carcieri C, Tomasello C, Simiele M, De Nicolo A, Avataneo V, Canzoneri L, et al. Cannabinoids concentration variability in cannabis olive oil galenic preparations. J Pharm Pharmacol. 2018;70(1):143–9.CrossRefPubMedGoogle Scholar
  124. 124.
    Dryburgh LM, Bolan NS, Grof CPL, Galettis P, Schneider J, Lucas CJ, et al. Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. Br J Clin Pharmacol. 2018;84(11):2468–76.CrossRefPubMedGoogle Scholar
  125. 125.
    Pavlovic R, Nenna G, Calvi L, Panseri S, Borgonovo G, Giupponi L, et al. Quality traits of “Cannabidiol Oils”: Cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules. 2018;23(5).Google Scholar
  126. 126.
    Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313(24):2491–3.CrossRefPubMedGoogle Scholar
  127. 127.
    Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardo FP, Pichini S. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med. 2017;55(10):1555–63.CrossRefPubMedGoogle Scholar
  128. 128.
    Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59(8):1540–8.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, et al. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018;87:131–6.CrossRefPubMedGoogle Scholar
  130. 130.
    Gaston T, Szaflarski M, Hansen B, Grayson L, Bebin EM, Szaflarski J. Improvement in quality of life ratings after one year of treatment with pharmaceutical formulation of cannabidiol (CBD). Epilepsia. 2017;58:S155.CrossRefGoogle Scholar
  131. 131.
    Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D. Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia. 2017;58(8):e96–100.CrossRefPubMedPubMedCentralGoogle Scholar
  132. 132.
    Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96.CrossRefPubMedGoogle Scholar
  133. 133.
    Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21(3):175–85.CrossRefPubMedGoogle Scholar
  134. 134.
    Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften. 1978;65(4):174–9.CrossRefPubMedGoogle Scholar
  135. 135.
    Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana ‘90 International Conference on Cannabis and Cannabinoids; July 8–11, 1990; Kolympari, Crete (cited by Devinsky et al. 2014).Google Scholar
  136. 136.
    Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1986;69(1):14.PubMedGoogle Scholar
  137. 137.
    Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014(3):CD009270.Google Scholar
  138. 138.
    Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556–63.CrossRefPubMedPubMedCentralGoogle Scholar
  139. 139.
    Miller I, Perry MS, Saneto RP, Scheffer I, Gunning B, Sanchez-Carpintero R, et al. Cannabidiol (CBD; 10 and 20 mg/kg/day) significantly reduces convulsive seizure frequency in children and adolescents with Dravet syndrome (DS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE2). [abstract]. Annual Meeting of the American Academy of Neurology, Philadelphia, May 4–10, 2019. http://file:///E:/2019-emerging-science-schedule-and-abstracts-with-disclosures.pdf. Accessed 13 May 2019.Google Scholar
  140. 140.
    Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419–28.CrossRefPubMedGoogle Scholar
  141. 141.
    Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019;60(2):294–302.CrossRefPubMedGoogle Scholar
  142. 142.
    Thiele EA, Devinsky O, Checketts D, Knappertz V. Cannabidiol treatment responder analysis in patients with Lennox-Gastaut syndrome on and off clobazam [abstract]. American Epilepsy Society Annual Meeting, New Orleans, LA, November 30–December 4, 2018. https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/381224. Accessed 04 Mar 2019.
  143. 143.
    Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78(17):1791–804.CrossRefPubMedGoogle Scholar
  144. 144.
    Sands TT, Rahdari S, Oldham MS, Caminha Nunes E, Tilton N, Cilio MR. Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: results from an expanded access program in the US. CNS Drugs. 2019;33(1):47–60.CrossRefPubMedGoogle Scholar
  145. 145.
    Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend. 2017;172:9–13.CrossRefPubMedGoogle Scholar
  146. 146.
    Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial. Epilepsy Behav. 2018;88:162–71.CrossRefPubMedGoogle Scholar
  147. 147.
    Schonhofen P, Bristot IJ, Crippa JA, Hallak JEC, Zuardi AW, Parsons RB, et al. Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system. CNS Drugs. 2018;32(8):697–712.CrossRefPubMedGoogle Scholar

via Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy | SpringerLink

, , , , , , ,

Leave a comment

%d bloggers like this: